Moderna CEO says data for Omicron-specific shot likely available in March

561
Comment
Favorite

Moderna CEO says data for Omicron-specific shot likely available in March

Reuters2022-01-17

Moderna Inc's vaccine candidate against the Omicron coronavirus variant will enter clinical development in the next few weeks and the company expects to be able to share data with regulators around ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

561

Report

Comment

Jonomega
·2022-01-18
Ok
Reply
1
Report
Liuliusg
·2022-01-18
Like
Reply
1
Report
hellodarz888
·2022-01-18
Lets hope the availability and efficacy are there
Reply
Like
Report
MHh
·2022-01-18
What does this mean for people who have already gotten their booster shot? Next round then jab this? Seems like covid vaccines areevery 6-9monthly and it is somewhat mandatory. Let’s not forget that every year millionsget influenza infections and other forms of pneumonia.
Reply
3
Report
PearlynCSY
·2022-01-18
Everywhere reporting record high cases of Omicron. US is the worst with over 1.3 million cases a day. Bad for global economic recovery. A Gen 2 vaccine is becoming more urgent to mitigate the pandemic
Reply
1
Report
EHG
·2022-01-18
Like
Reply
1
Report
Cw_88
·2022-01-18
Like
Reply
2
Report
HuatGirl
·2022-01-18
Done
Reply
1
Report
Pandachubby
·2022-01-18
Ok
Reply
3
Report
WindyMoon
·2022-01-18
[Cool]
Reply
2
Report
Ah Deck
·2022-01-18
Pls like
Reply
1
Report
LameDude
·2022-01-18
Like
Reply
1
Report
Success88
·2022-01-18
Yeah
Reply
3
Report
Tyanak
·2022-01-18
👍🏻
Reply
2
Report
whitesnake
·2022-01-18
👍🏻
Reply
1
Report
SiewMailing
·2022-01-18
Ok
Reply
2
Report
Rbj
·2022-01-18
Great
Reply
2
Report
jerwy
·2022-01-18
wow
Reply
3
Report
Whateverqw
·2022-01-18
Fast
Reply
3
Report
MO75
·2022-01-18
Siao. Like
Reply
8
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2204577605?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2022-01-17 22:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2204577605","market":"us","top_or_hot":-1,"title":"Moderna CEO says data for Omicron-specific shot likely available in March","media":"Reuters","content":"<div>\n<p>Moderna Inc's vaccine candidate against the Omicron coronavirus variant will enter clinical development in the next few weeks and the company expects to be able to share data with regulators around ...</p>\n\n<a href=\"https://finance.yahoo.com/news/moderna-ceo-says-data-omicron-135958538.html\">Source Link</a>\n\n</div>\n","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna CEO says data for Omicron-specific shot likely available in March</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna CEO says data for Omicron-specific shot likely available in March\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-17 22:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/moderna-ceo-says-data-omicron-135958538.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Moderna Inc's vaccine candidate against the Omicron coronavirus variant will enter clinical development in the next few weeks and the company expects to be able to share data with regulators around ...</p>\n\n<a href=\"https://finance.yahoo.com/news/moderna-ceo-says-data-omicron-135958538.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4534","symbol_name":"瑞士信贷持仓","start_time":0,"source_url":"https://finance.yahoo.com/news/moderna-ceo-says-data-omicron-135958538.html","article_id":"2204577605","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2204577605","pubTimestamp":1642431461,"sourceInfo":null,"weMediaInfo":null,"summary":"Moderna Inc's vaccine candidate against the Omicron coronavirus variant will enter clinical developm","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4534":"瑞士信贷持仓","BK4139":"生物科技","MRNA":"Moderna, Inc.","BK4568":"美国抗疫概念","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4548":"巴美列捷福持仓","BK4532":"文艺复兴科技持仓","BK4551":"寇图资本持仓","BNTX":"BioNTech SE","BK4535":"淡马锡持仓"},"translate_title":"莫德纳首席执行官表示，奥密克戎特定镜头的数据可能会在3月份公布","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"832000":1,"832089":1,"832145":1,"832171":1,"832225":1,"832278":1,"832317":1,"832566":1,"832735":1,"832885":1,"MRNA":0.9,"BNTX":0.76},"content_text":"Moderna Inc's vaccine candidate against the Omicron coronavirus variant will enter clinical development in the next few weeks and the company expects to be able to share data with regulators around March, CEO Stephane Bancel said on Monday.\"The vaccine is being finished ... it should be in the clinic in coming weeks. We are hoping in the March timeframe to be able to have data to share with regulators to figure out next steps,\" Bancel said at the World Economic Forum's virtual Davos Agenda conference.Moderna is also developing a single vaccine that combines a booster dose against COVID-19 with its experimental flu shot. ()Bancel said the best case scenario was the combined COVID/flu vaccine would be available by the fall of 2023, at least in some countries.\"Our goal is to be able to have a single annual booster so that we don't have compliance issues where people don't want to get two to three shots a winter.\"Many countries are already offering a third dose of a COVID-19 vaccine to their citizens, especially to older individuals and those who are immunocompromised, while Israel has started offering its citizens a fourth dose.Earlier in January, Moderna's CEO said people may need a fourth shot in the fall of 2022 as the efficacy of boosters against COVID-19 was likely to decline over the next few months.However, booster programs have met with skepticism from some disease experts over whether, and how widely, additional doses should become available, including the European Union's drug regulator, which has expressed doubts about the need for a fourth booster dose.Speaking at the same event, top U.S. infectious disease expert Anthony Fauci said there was no evidence that repeat booster doses would overwhelm the immune system.\"Giving boosters at different times, there is really no evidence that's going to hinder (immune response).\"Fauci said the goal should be to have a booster that induces a response against multiple potential variants.","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[{"id":9004938877,"gmtCreate":1642469291900,"gmtModify":1676533713512,"author":{"id":"3584676472176133","authorId":"3584676472176133","name":"Jonomega","avatar":"https://static.tigerbbs.com/1b4c775ad26d4d9b90ba50498708426a","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9004938877","repostId":2204577605,"repostType":2,"repost":{"id":"2204577605","pubTimestamp":1642431461,"share":"https://www.laohu8.com/m/news/2204577605?lang=&edition=full","pubTime":"2022-01-17 22:57","market":"us","language":"en","title":"Moderna CEO says data for Omicron-specific shot likely available in March","url":"https://stock-news.laohu8.com/highlight/detail?id=2204577605","media":"Reuters","summary":"Moderna Inc's vaccine candidate against the Omicron coronavirus variant will enter clinical developm","content":"<html><head></head><body><p>Moderna Inc&#39;s vaccine candidate against the Omicron coronavirus variant will enter clinical development in the next few weeks and the company expects to be able to share data with regulators around March, CEO Stephane Bancel said on Monday.</p><p>&#34;The vaccine is being finished ... it should be in the clinic in coming weeks. We are hoping in the March timeframe to be able to have data to share with regulators to figure out next steps,&#34; Bancel said at the World Economic Forum&#39;s virtual Davos Agenda conference.</p><p>Moderna is also developing a single vaccine that combines a booster dose against COVID-19 with its experimental flu shot. ()</p><p>Bancel said the best case scenario was the combined COVID/flu vaccine would be available by the fall of 2023, at least in some countries.</p><p>&#34;Our goal is to be able to have a single annual booster so that we don&#39;t have compliance issues where people don&#39;t want to get two to three shots a winter.&#34;</p><p>Many countries are already offering a third dose of a COVID-19 vaccine to their citizens, especially to older individuals and those who are immunocompromised, while Israel has started offering its citizens a fourth dose.</p><p>Earlier in January, Moderna&#39;s CEO said people may need a fourth shot in the fall of 2022 as the efficacy of boosters against COVID-19 was likely to decline over the next few months.</p><p>However, booster programs have met with skepticism from some disease experts over whether, and how widely, additional doses should become available, including the European Union&#39;s drug regulator, which has expressed doubts about the need for a fourth booster dose.</p><p>Speaking at the same event, top U.S. infectious disease expert Anthony Fauci said there was no evidence that repeat booster doses would overwhelm the immune system.</p><p>&#34;Giving boosters at different times, there is really no evidence that&#39;s going to hinder (immune response).&#34;</p><p>Fauci said the goal should be to have a booster that induces a response against multiple potential variants.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna CEO says data for Omicron-specific shot likely available in March</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna CEO says data for Omicron-specific shot likely available in March\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-17 22:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/moderna-ceo-says-data-omicron-135958538.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Moderna Inc's vaccine candidate against the Omicron coronavirus variant will enter clinical development in the next few weeks and the company expects to be able to share data with regulators around ...</p>\n\n<a href=\"https://finance.yahoo.com/news/moderna-ceo-says-data-omicron-135958538.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4533":"AQR资本管理(全球第二大对冲基金)","BK4568":"美国抗疫概念","BNTX":"BioNTech SE","BK4532":"文艺复兴科技持仓","BK4551":"寇图资本持仓","BK4548":"巴美列捷福持仓","BK4535":"淡马锡持仓","MRNA":"Moderna, Inc.","BK4534":"瑞士信贷持仓","BK4139":"生物科技"},"source_url":"https://finance.yahoo.com/news/moderna-ceo-says-data-omicron-135958538.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2204577605","content_text":"Moderna Inc's vaccine candidate against the Omicron coronavirus variant will enter clinical development in the next few weeks and the company expects to be able to share data with regulators around March, CEO Stephane Bancel said on Monday.\"The vaccine is being finished ... it should be in the clinic in coming weeks. We are hoping in the March timeframe to be able to have data to share with regulators to figure out next steps,\" Bancel said at the World Economic Forum's virtual Davos Agenda conference.Moderna is also developing a single vaccine that combines a booster dose against COVID-19 with its experimental flu shot. ()Bancel said the best case scenario was the combined COVID/flu vaccine would be available by the fall of 2023, at least in some countries.\"Our goal is to be able to have a single annual booster so that we don't have compliance issues where people don't want to get two to three shots a winter.\"Many countries are already offering a third dose of a COVID-19 vaccine to their citizens, especially to older individuals and those who are immunocompromised, while Israel has started offering its citizens a fourth dose.Earlier in January, Moderna's CEO said people may need a fourth shot in the fall of 2022 as the efficacy of boosters against COVID-19 was likely to decline over the next few months.However, booster programs have met with skepticism from some disease experts over whether, and how widely, additional doses should become available, including the European Union's drug regulator, which has expressed doubts about the need for a fourth booster dose.Speaking at the same event, top U.S. infectious disease expert Anthony Fauci said there was no evidence that repeat booster doses would overwhelm the immune system.\"Giving boosters at different times, there is really no evidence that's going to hinder (immune response).\"Fauci said the goal should be to have a booster that induces a response against multiple potential variants.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9004070862,"gmtCreate":1642464930067,"gmtModify":1676533712491,"author":{"id":"3571112889855060","authorId":"3571112889855060","name":"Liuliusg","avatar":"https://static.tigerbbs.com/86e7691637ffe866f31f181dbe2ede72","vip":1,"crmLevel":5,"crmLevelSwitch":0},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9004070862","repostId":2204577605,"repostType":4,"repost":{"id":"2204577605","pubTimestamp":1642431461,"share":"https://www.laohu8.com/m/news/2204577605?lang=&edition=full","pubTime":"2022-01-17 22:57","market":"us","language":"en","title":"Moderna CEO says data for Omicron-specific shot likely available in March","url":"https://stock-news.laohu8.com/highlight/detail?id=2204577605","media":"Reuters","summary":"Moderna Inc's vaccine candidate against the Omicron coronavirus variant will enter clinical developm","content":"<html><head></head><body><p>Moderna Inc&#39;s vaccine candidate against the Omicron coronavirus variant will enter clinical development in the next few weeks and the company expects to be able to share data with regulators around March, CEO Stephane Bancel said on Monday.</p><p>&#34;The vaccine is being finished ... it should be in the clinic in coming weeks. We are hoping in the March timeframe to be able to have data to share with regulators to figure out next steps,&#34; Bancel said at the World Economic Forum&#39;s virtual Davos Agenda conference.</p><p>Moderna is also developing a single vaccine that combines a booster dose against COVID-19 with its experimental flu shot. ()</p><p>Bancel said the best case scenario was the combined COVID/flu vaccine would be available by the fall of 2023, at least in some countries.</p><p>&#34;Our goal is to be able to have a single annual booster so that we don&#39;t have compliance issues where people don&#39;t want to get two to three shots a winter.&#34;</p><p>Many countries are already offering a third dose of a COVID-19 vaccine to their citizens, especially to older individuals and those who are immunocompromised, while Israel has started offering its citizens a fourth dose.</p><p>Earlier in January, Moderna&#39;s CEO said people may need a fourth shot in the fall of 2022 as the efficacy of boosters against COVID-19 was likely to decline over the next few months.</p><p>However, booster programs have met with skepticism from some disease experts over whether, and how widely, additional doses should become available, including the European Union&#39;s drug regulator, which has expressed doubts about the need for a fourth booster dose.</p><p>Speaking at the same event, top U.S. infectious disease expert Anthony Fauci said there was no evidence that repeat booster doses would overwhelm the immune system.</p><p>&#34;Giving boosters at different times, there is really no evidence that&#39;s going to hinder (immune response).&#34;</p><p>Fauci said the goal should be to have a booster that induces a response against multiple potential variants.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna CEO says data for Omicron-specific shot likely available in March</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna CEO says data for Omicron-specific shot likely available in March\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-17 22:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/moderna-ceo-says-data-omicron-135958538.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Moderna Inc's vaccine candidate against the Omicron coronavirus variant will enter clinical development in the next few weeks and the company expects to be able to share data with regulators around ...</p>\n\n<a href=\"https://finance.yahoo.com/news/moderna-ceo-says-data-omicron-135958538.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4533":"AQR资本管理(全球第二大对冲基金)","BK4568":"美国抗疫概念","BNTX":"BioNTech SE","BK4532":"文艺复兴科技持仓","BK4551":"寇图资本持仓","BK4548":"巴美列捷福持仓","BK4535":"淡马锡持仓","MRNA":"Moderna, Inc.","BK4534":"瑞士信贷持仓","BK4139":"生物科技"},"source_url":"https://finance.yahoo.com/news/moderna-ceo-says-data-omicron-135958538.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2204577605","content_text":"Moderna Inc's vaccine candidate against the Omicron coronavirus variant will enter clinical development in the next few weeks and the company expects to be able to share data with regulators around March, CEO Stephane Bancel said on Monday.\"The vaccine is being finished ... it should be in the clinic in coming weeks. We are hoping in the March timeframe to be able to have data to share with regulators to figure out next steps,\" Bancel said at the World Economic Forum's virtual Davos Agenda conference.Moderna is also developing a single vaccine that combines a booster dose against COVID-19 with its experimental flu shot. ()Bancel said the best case scenario was the combined COVID/flu vaccine would be available by the fall of 2023, at least in some countries.\"Our goal is to be able to have a single annual booster so that we don't have compliance issues where people don't want to get two to three shots a winter.\"Many countries are already offering a third dose of a COVID-19 vaccine to their citizens, especially to older individuals and those who are immunocompromised, while Israel has started offering its citizens a fourth dose.Earlier in January, Moderna's CEO said people may need a fourth shot in the fall of 2022 as the efficacy of boosters against COVID-19 was likely to decline over the next few months.However, booster programs have met with skepticism from some disease experts over whether, and how widely, additional doses should become available, including the European Union's drug regulator, which has expressed doubts about the need for a fourth booster dose.Speaking at the same event, top U.S. infectious disease expert Anthony Fauci said there was no evidence that repeat booster doses would overwhelm the immune system.\"Giving boosters at different times, there is really no evidence that's going to hinder (immune response).\"Fauci said the goal should be to have a booster that induces a response against multiple potential variants.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9004044046,"gmtCreate":1642464660193,"gmtModify":1676533712427,"author":{"id":"3583033675115574","authorId":"3583033675115574","name":"hellodarz888","avatar":"https://static.tigerbbs.com/4e5f7fa39ea3c821aa8099f517287dcb","vip":1,"crmLevel":8,"crmLevelSwitch":1},"htmlText":"Lets hope the availability and efficacy are there","listText":"Lets hope the availability and efficacy are there","text":"Lets hope the availability and efficacy are there","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9004044046","repostId":2204577605,"repostType":4,"repost":{"id":"2204577605","pubTimestamp":1642431461,"share":"https://www.laohu8.com/m/news/2204577605?lang=&edition=full","pubTime":"2022-01-17 22:57","market":"us","language":"en","title":"Moderna CEO says data for Omicron-specific shot likely available in March","url":"https://stock-news.laohu8.com/highlight/detail?id=2204577605","media":"Reuters","summary":"Moderna Inc's vaccine candidate against the Omicron coronavirus variant will enter clinical developm","content":"<html><head></head><body><p>Moderna Inc&#39;s vaccine candidate against the Omicron coronavirus variant will enter clinical development in the next few weeks and the company expects to be able to share data with regulators around March, CEO Stephane Bancel said on Monday.</p><p>&#34;The vaccine is being finished ... it should be in the clinic in coming weeks. We are hoping in the March timeframe to be able to have data to share with regulators to figure out next steps,&#34; Bancel said at the World Economic Forum&#39;s virtual Davos Agenda conference.</p><p>Moderna is also developing a single vaccine that combines a booster dose against COVID-19 with its experimental flu shot. ()</p><p>Bancel said the best case scenario was the combined COVID/flu vaccine would be available by the fall of 2023, at least in some countries.</p><p>&#34;Our goal is to be able to have a single annual booster so that we don&#39;t have compliance issues where people don&#39;t want to get two to three shots a winter.&#34;</p><p>Many countries are already offering a third dose of a COVID-19 vaccine to their citizens, especially to older individuals and those who are immunocompromised, while Israel has started offering its citizens a fourth dose.</p><p>Earlier in January, Moderna&#39;s CEO said people may need a fourth shot in the fall of 2022 as the efficacy of boosters against COVID-19 was likely to decline over the next few months.</p><p>However, booster programs have met with skepticism from some disease experts over whether, and how widely, additional doses should become available, including the European Union&#39;s drug regulator, which has expressed doubts about the need for a fourth booster dose.</p><p>Speaking at the same event, top U.S. infectious disease expert Anthony Fauci said there was no evidence that repeat booster doses would overwhelm the immune system.</p><p>&#34;Giving boosters at different times, there is really no evidence that&#39;s going to hinder (immune response).&#34;</p><p>Fauci said the goal should be to have a booster that induces a response against multiple potential variants.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna CEO says data for Omicron-specific shot likely available in March</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna CEO says data for Omicron-specific shot likely available in March\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-17 22:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/moderna-ceo-says-data-omicron-135958538.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Moderna Inc's vaccine candidate against the Omicron coronavirus variant will enter clinical development in the next few weeks and the company expects to be able to share data with regulators around ...</p>\n\n<a href=\"https://finance.yahoo.com/news/moderna-ceo-says-data-omicron-135958538.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4533":"AQR资本管理(全球第二大对冲基金)","BK4568":"美国抗疫概念","BNTX":"BioNTech SE","BK4532":"文艺复兴科技持仓","BK4551":"寇图资本持仓","BK4548":"巴美列捷福持仓","BK4535":"淡马锡持仓","MRNA":"Moderna, Inc.","BK4534":"瑞士信贷持仓","BK4139":"生物科技"},"source_url":"https://finance.yahoo.com/news/moderna-ceo-says-data-omicron-135958538.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2204577605","content_text":"Moderna Inc's vaccine candidate against the Omicron coronavirus variant will enter clinical development in the next few weeks and the company expects to be able to share data with regulators around March, CEO Stephane Bancel said on Monday.\"The vaccine is being finished ... it should be in the clinic in coming weeks. We are hoping in the March timeframe to be able to have data to share with regulators to figure out next steps,\" Bancel said at the World Economic Forum's virtual Davos Agenda conference.Moderna is also developing a single vaccine that combines a booster dose against COVID-19 with its experimental flu shot. ()Bancel said the best case scenario was the combined COVID/flu vaccine would be available by the fall of 2023, at least in some countries.\"Our goal is to be able to have a single annual booster so that we don't have compliance issues where people don't want to get two to three shots a winter.\"Many countries are already offering a third dose of a COVID-19 vaccine to their citizens, especially to older individuals and those who are immunocompromised, while Israel has started offering its citizens a fourth dose.Earlier in January, Moderna's CEO said people may need a fourth shot in the fall of 2022 as the efficacy of boosters against COVID-19 was likely to decline over the next few months.However, booster programs have met with skepticism from some disease experts over whether, and how widely, additional doses should become available, including the European Union's drug regulator, which has expressed doubts about the need for a fourth booster dose.Speaking at the same event, top U.S. infectious disease expert Anthony Fauci said there was no evidence that repeat booster doses would overwhelm the immune system.\"Giving boosters at different times, there is really no evidence that's going to hinder (immune response).\"Fauci said the goal should be to have a booster that induces a response against multiple potential variants.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9004058146,"gmtCreate":1642463274933,"gmtModify":1676533712092,"author":{"id":"4091758936365950","authorId":"4091758936365950","name":"MHh","avatar":"https://static.tigerbbs.com/54b2feced9ef5dcc9e95997d1f4db280","vip":1,"crmLevel":6,"crmLevelSwitch":1},"htmlText":"What does this mean for people who have already gotten their booster shot? Next round then jab this? Seems like covid vaccines areevery 6-9monthly and it is somewhat mandatory. Let’s not forget that every year millionsget influenza infections and other forms of pneumonia.","listText":"What does this mean for people who have already gotten their booster shot? Next round then jab this? Seems like covid vaccines areevery 6-9monthly and it is somewhat mandatory. Let’s not forget that every year millionsget influenza infections and other forms of pneumonia.","text":"What does this mean for people who have already gotten their booster shot? Next round then jab this? Seems like covid vaccines areevery 6-9monthly and it is somewhat mandatory. Let’s not forget that every year millionsget influenza infections and other forms of pneumonia.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9004058146","repostId":2204577605,"repostType":4,"repost":{"id":"2204577605","pubTimestamp":1642431461,"share":"https://www.laohu8.com/m/news/2204577605?lang=&edition=full","pubTime":"2022-01-17 22:57","market":"us","language":"en","title":"Moderna CEO says data for Omicron-specific shot likely available in March","url":"https://stock-news.laohu8.com/highlight/detail?id=2204577605","media":"Reuters","summary":"Moderna Inc's vaccine candidate against the Omicron coronavirus variant will enter clinical developm","content":"<html><head></head><body><p>Moderna Inc&#39;s vaccine candidate against the Omicron coronavirus variant will enter clinical development in the next few weeks and the company expects to be able to share data with regulators around March, CEO Stephane Bancel said on Monday.</p><p>&#34;The vaccine is being finished ... it should be in the clinic in coming weeks. We are hoping in the March timeframe to be able to have data to share with regulators to figure out next steps,&#34; Bancel said at the World Economic Forum&#39;s virtual Davos Agenda conference.</p><p>Moderna is also developing a single vaccine that combines a booster dose against COVID-19 with its experimental flu shot. ()</p><p>Bancel said the best case scenario was the combined COVID/flu vaccine would be available by the fall of 2023, at least in some countries.</p><p>&#34;Our goal is to be able to have a single annual booster so that we don&#39;t have compliance issues where people don&#39;t want to get two to three shots a winter.&#34;</p><p>Many countries are already offering a third dose of a COVID-19 vaccine to their citizens, especially to older individuals and those who are immunocompromised, while Israel has started offering its citizens a fourth dose.</p><p>Earlier in January, Moderna&#39;s CEO said people may need a fourth shot in the fall of 2022 as the efficacy of boosters against COVID-19 was likely to decline over the next few months.</p><p>However, booster programs have met with skepticism from some disease experts over whether, and how widely, additional doses should become available, including the European Union&#39;s drug regulator, which has expressed doubts about the need for a fourth booster dose.</p><p>Speaking at the same event, top U.S. infectious disease expert Anthony Fauci said there was no evidence that repeat booster doses would overwhelm the immune system.</p><p>&#34;Giving boosters at different times, there is really no evidence that&#39;s going to hinder (immune response).&#34;</p><p>Fauci said the goal should be to have a booster that induces a response against multiple potential variants.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna CEO says data for Omicron-specific shot likely available in March</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna CEO says data for Omicron-specific shot likely available in March\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-17 22:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/moderna-ceo-says-data-omicron-135958538.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Moderna Inc's vaccine candidate against the Omicron coronavirus variant will enter clinical development in the next few weeks and the company expects to be able to share data with regulators around ...</p>\n\n<a href=\"https://finance.yahoo.com/news/moderna-ceo-says-data-omicron-135958538.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4533":"AQR资本管理(全球第二大对冲基金)","BK4568":"美国抗疫概念","BNTX":"BioNTech SE","BK4532":"文艺复兴科技持仓","BK4551":"寇图资本持仓","BK4548":"巴美列捷福持仓","BK4535":"淡马锡持仓","MRNA":"Moderna, Inc.","BK4534":"瑞士信贷持仓","BK4139":"生物科技"},"source_url":"https://finance.yahoo.com/news/moderna-ceo-says-data-omicron-135958538.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2204577605","content_text":"Moderna Inc's vaccine candidate against the Omicron coronavirus variant will enter clinical development in the next few weeks and the company expects to be able to share data with regulators around March, CEO Stephane Bancel said on Monday.\"The vaccine is being finished ... it should be in the clinic in coming weeks. We are hoping in the March timeframe to be able to have data to share with regulators to figure out next steps,\" Bancel said at the World Economic Forum's virtual Davos Agenda conference.Moderna is also developing a single vaccine that combines a booster dose against COVID-19 with its experimental flu shot. ()Bancel said the best case scenario was the combined COVID/flu vaccine would be available by the fall of 2023, at least in some countries.\"Our goal is to be able to have a single annual booster so that we don't have compliance issues where people don't want to get two to three shots a winter.\"Many countries are already offering a third dose of a COVID-19 vaccine to their citizens, especially to older individuals and those who are immunocompromised, while Israel has started offering its citizens a fourth dose.Earlier in January, Moderna's CEO said people may need a fourth shot in the fall of 2022 as the efficacy of boosters against COVID-19 was likely to decline over the next few months.However, booster programs have met with skepticism from some disease experts over whether, and how widely, additional doses should become available, including the European Union's drug regulator, which has expressed doubts about the need for a fourth booster dose.Speaking at the same event, top U.S. infectious disease expert Anthony Fauci said there was no evidence that repeat booster doses would overwhelm the immune system.\"Giving boosters at different times, there is really no evidence that's going to hinder (immune response).\"Fauci said the goal should be to have a booster that induces a response against multiple potential variants.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9004027739,"gmtCreate":1642462754751,"gmtModify":1676533712004,"author":{"id":"4092458811577680","authorId":"4092458811577680","name":"PearlynCSY","avatar":"https://static.tigerbbs.com/b3e9fe7af061efe80a756d23de62e7b3","vip":1,"crmLevel":4,"crmLevelSwitch":1},"htmlText":"Everywhere reporting record high cases of Omicron. US is the worst with over 1.3 million cases a day. Bad for global economic recovery. A Gen 2 vaccine is becoming more urgent&nbsp;to mitigate the pandemic","listText":"Everywhere reporting record high cases of Omicron. US is the worst with over 1.3 million cases a day. Bad for global economic recovery. A Gen 2 vaccine is becoming more urgent&nbsp;to mitigate the pandemic","text":"Everywhere reporting record high cases of Omicron. US is the worst with over 1.3 million cases a day. Bad for global economic recovery. A Gen 2 vaccine is becoming more urgent to mitigate the pandemic","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9004027739","repostId":2204577605,"repostType":4,"repost":{"id":"2204577605","pubTimestamp":1642431461,"share":"https://www.laohu8.com/m/news/2204577605?lang=&edition=full","pubTime":"2022-01-17 22:57","market":"us","language":"en","title":"Moderna CEO says data for Omicron-specific shot likely available in March","url":"https://stock-news.laohu8.com/highlight/detail?id=2204577605","media":"Reuters","summary":"Moderna Inc's vaccine candidate against the Omicron coronavirus variant will enter clinical developm","content":"<html><head></head><body><p>Moderna Inc&#39;s vaccine candidate against the Omicron coronavirus variant will enter clinical development in the next few weeks and the company expects to be able to share data with regulators around March, CEO Stephane Bancel said on Monday.</p><p>&#34;The vaccine is being finished ... it should be in the clinic in coming weeks. We are hoping in the March timeframe to be able to have data to share with regulators to figure out next steps,&#34; Bancel said at the World Economic Forum&#39;s virtual Davos Agenda conference.</p><p>Moderna is also developing a single vaccine that combines a booster dose against COVID-19 with its experimental flu shot. ()</p><p>Bancel said the best case scenario was the combined COVID/flu vaccine would be available by the fall of 2023, at least in some countries.</p><p>&#34;Our goal is to be able to have a single annual booster so that we don&#39;t have compliance issues where people don&#39;t want to get two to three shots a winter.&#34;</p><p>Many countries are already offering a third dose of a COVID-19 vaccine to their citizens, especially to older individuals and those who are immunocompromised, while Israel has started offering its citizens a fourth dose.</p><p>Earlier in January, Moderna&#39;s CEO said people may need a fourth shot in the fall of 2022 as the efficacy of boosters against COVID-19 was likely to decline over the next few months.</p><p>However, booster programs have met with skepticism from some disease experts over whether, and how widely, additional doses should become available, including the European Union&#39;s drug regulator, which has expressed doubts about the need for a fourth booster dose.</p><p>Speaking at the same event, top U.S. infectious disease expert Anthony Fauci said there was no evidence that repeat booster doses would overwhelm the immune system.</p><p>&#34;Giving boosters at different times, there is really no evidence that&#39;s going to hinder (immune response).&#34;</p><p>Fauci said the goal should be to have a booster that induces a response against multiple potential variants.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna CEO says data for Omicron-specific shot likely available in March</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna CEO says data for Omicron-specific shot likely available in March\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-17 22:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/moderna-ceo-says-data-omicron-135958538.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Moderna Inc's vaccine candidate against the Omicron coronavirus variant will enter clinical development in the next few weeks and the company expects to be able to share data with regulators around ...</p>\n\n<a href=\"https://finance.yahoo.com/news/moderna-ceo-says-data-omicron-135958538.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4533":"AQR资本管理(全球第二大对冲基金)","BK4568":"美国抗疫概念","BNTX":"BioNTech SE","BK4532":"文艺复兴科技持仓","BK4551":"寇图资本持仓","BK4548":"巴美列捷福持仓","BK4535":"淡马锡持仓","MRNA":"Moderna, Inc.","BK4534":"瑞士信贷持仓","BK4139":"生物科技"},"source_url":"https://finance.yahoo.com/news/moderna-ceo-says-data-omicron-135958538.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2204577605","content_text":"Moderna Inc's vaccine candidate against the Omicron coronavirus variant will enter clinical development in the next few weeks and the company expects to be able to share data with regulators around March, CEO Stephane Bancel said on Monday.\"The vaccine is being finished ... it should be in the clinic in coming weeks. We are hoping in the March timeframe to be able to have data to share with regulators to figure out next steps,\" Bancel said at the World Economic Forum's virtual Davos Agenda conference.Moderna is also developing a single vaccine that combines a booster dose against COVID-19 with its experimental flu shot. ()Bancel said the best case scenario was the combined COVID/flu vaccine would be available by the fall of 2023, at least in some countries.\"Our goal is to be able to have a single annual booster so that we don't have compliance issues where people don't want to get two to three shots a winter.\"Many countries are already offering a third dose of a COVID-19 vaccine to their citizens, especially to older individuals and those who are immunocompromised, while Israel has started offering its citizens a fourth dose.Earlier in January, Moderna's CEO said people may need a fourth shot in the fall of 2022 as the efficacy of boosters against COVID-19 was likely to decline over the next few months.However, booster programs have met with skepticism from some disease experts over whether, and how widely, additional doses should become available, including the European Union's drug regulator, which has expressed doubts about the need for a fourth booster dose.Speaking at the same event, top U.S. infectious disease expert Anthony Fauci said there was no evidence that repeat booster doses would overwhelm the immune system.\"Giving boosters at different times, there is really no evidence that's going to hinder (immune response).\"Fauci said the goal should be to have a booster that induces a response against multiple potential variants.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9004025421,"gmtCreate":1642462518723,"gmtModify":1676533711876,"author":{"id":"3586941861951066","authorId":"3586941861951066","name":"EHG","avatar":"https://static.tigerbbs.com/28e4734e50f795c3218330cbb6c3e9a0","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Like&nbsp;","listText":"Like&nbsp;","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9004025421","repostId":2204577605,"repostType":4,"repost":{"id":"2204577605","pubTimestamp":1642431461,"share":"https://www.laohu8.com/m/news/2204577605?lang=&edition=full","pubTime":"2022-01-17 22:57","market":"us","language":"en","title":"Moderna CEO says data for Omicron-specific shot likely available in March","url":"https://stock-news.laohu8.com/highlight/detail?id=2204577605","media":"Reuters","summary":"Moderna Inc's vaccine candidate against the Omicron coronavirus variant will enter clinical developm","content":"<html><head></head><body><p>Moderna Inc&#39;s vaccine candidate against the Omicron coronavirus variant will enter clinical development in the next few weeks and the company expects to be able to share data with regulators around March, CEO Stephane Bancel said on Monday.</p><p>&#34;The vaccine is being finished ... it should be in the clinic in coming weeks. We are hoping in the March timeframe to be able to have data to share with regulators to figure out next steps,&#34; Bancel said at the World Economic Forum&#39;s virtual Davos Agenda conference.</p><p>Moderna is also developing a single vaccine that combines a booster dose against COVID-19 with its experimental flu shot. ()</p><p>Bancel said the best case scenario was the combined COVID/flu vaccine would be available by the fall of 2023, at least in some countries.</p><p>&#34;Our goal is to be able to have a single annual booster so that we don&#39;t have compliance issues where people don&#39;t want to get two to three shots a winter.&#34;</p><p>Many countries are already offering a third dose of a COVID-19 vaccine to their citizens, especially to older individuals and those who are immunocompromised, while Israel has started offering its citizens a fourth dose.</p><p>Earlier in January, Moderna&#39;s CEO said people may need a fourth shot in the fall of 2022 as the efficacy of boosters against COVID-19 was likely to decline over the next few months.</p><p>However, booster programs have met with skepticism from some disease experts over whether, and how widely, additional doses should become available, including the European Union&#39;s drug regulator, which has expressed doubts about the need for a fourth booster dose.</p><p>Speaking at the same event, top U.S. infectious disease expert Anthony Fauci said there was no evidence that repeat booster doses would overwhelm the immune system.</p><p>&#34;Giving boosters at different times, there is really no evidence that&#39;s going to hinder (immune response).&#34;</p><p>Fauci said the goal should be to have a booster that induces a response against multiple potential variants.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna CEO says data for Omicron-specific shot likely available in March</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna CEO says data for Omicron-specific shot likely available in March\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-17 22:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/moderna-ceo-says-data-omicron-135958538.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Moderna Inc's vaccine candidate against the Omicron coronavirus variant will enter clinical development in the next few weeks and the company expects to be able to share data with regulators around ...</p>\n\n<a href=\"https://finance.yahoo.com/news/moderna-ceo-says-data-omicron-135958538.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4533":"AQR资本管理(全球第二大对冲基金)","BK4568":"美国抗疫概念","BNTX":"BioNTech SE","BK4532":"文艺复兴科技持仓","BK4551":"寇图资本持仓","BK4548":"巴美列捷福持仓","BK4535":"淡马锡持仓","MRNA":"Moderna, Inc.","BK4534":"瑞士信贷持仓","BK4139":"生物科技"},"source_url":"https://finance.yahoo.com/news/moderna-ceo-says-data-omicron-135958538.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2204577605","content_text":"Moderna Inc's vaccine candidate against the Omicron coronavirus variant will enter clinical development in the next few weeks and the company expects to be able to share data with regulators around March, CEO Stephane Bancel said on Monday.\"The vaccine is being finished ... it should be in the clinic in coming weeks. We are hoping in the March timeframe to be able to have data to share with regulators to figure out next steps,\" Bancel said at the World Economic Forum's virtual Davos Agenda conference.Moderna is also developing a single vaccine that combines a booster dose against COVID-19 with its experimental flu shot. ()Bancel said the best case scenario was the combined COVID/flu vaccine would be available by the fall of 2023, at least in some countries.\"Our goal is to be able to have a single annual booster so that we don't have compliance issues where people don't want to get two to three shots a winter.\"Many countries are already offering a third dose of a COVID-19 vaccine to their citizens, especially to older individuals and those who are immunocompromised, while Israel has started offering its citizens a fourth dose.Earlier in January, Moderna's CEO said people may need a fourth shot in the fall of 2022 as the efficacy of boosters against COVID-19 was likely to decline over the next few months.However, booster programs have met with skepticism from some disease experts over whether, and how widely, additional doses should become available, including the European Union's drug regulator, which has expressed doubts about the need for a fourth booster dose.Speaking at the same event, top U.S. infectious disease expert Anthony Fauci said there was no evidence that repeat booster doses would overwhelm the immune system.\"Giving boosters at different times, there is really no evidence that's going to hinder (immune response).\"Fauci said the goal should be to have a booster that induces a response against multiple potential variants.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9004025060,"gmtCreate":1642462480295,"gmtModify":1676533711867,"author":{"id":"3582802124387192","authorId":"3582802124387192","name":"Cw_88","avatar":"https://static.tigerbbs.com/73601b77e177185676fe499badeea2f7","vip":1,"crmLevel":1,"crmLevelSwitch":0},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9004025060","repostId":2204577605,"repostType":4,"repost":{"id":"2204577605","pubTimestamp":1642431461,"share":"https://www.laohu8.com/m/news/2204577605?lang=&edition=full","pubTime":"2022-01-17 22:57","market":"us","language":"en","title":"Moderna CEO says data for Omicron-specific shot likely available in March","url":"https://stock-news.laohu8.com/highlight/detail?id=2204577605","media":"Reuters","summary":"Moderna Inc's vaccine candidate against the Omicron coronavirus variant will enter clinical developm","content":"<html><head></head><body><p>Moderna Inc&#39;s vaccine candidate against the Omicron coronavirus variant will enter clinical development in the next few weeks and the company expects to be able to share data with regulators around March, CEO Stephane Bancel said on Monday.</p><p>&#34;The vaccine is being finished ... it should be in the clinic in coming weeks. We are hoping in the March timeframe to be able to have data to share with regulators to figure out next steps,&#34; Bancel said at the World Economic Forum&#39;s virtual Davos Agenda conference.</p><p>Moderna is also developing a single vaccine that combines a booster dose against COVID-19 with its experimental flu shot. ()</p><p>Bancel said the best case scenario was the combined COVID/flu vaccine would be available by the fall of 2023, at least in some countries.</p><p>&#34;Our goal is to be able to have a single annual booster so that we don&#39;t have compliance issues where people don&#39;t want to get two to three shots a winter.&#34;</p><p>Many countries are already offering a third dose of a COVID-19 vaccine to their citizens, especially to older individuals and those who are immunocompromised, while Israel has started offering its citizens a fourth dose.</p><p>Earlier in January, Moderna&#39;s CEO said people may need a fourth shot in the fall of 2022 as the efficacy of boosters against COVID-19 was likely to decline over the next few months.</p><p>However, booster programs have met with skepticism from some disease experts over whether, and how widely, additional doses should become available, including the European Union&#39;s drug regulator, which has expressed doubts about the need for a fourth booster dose.</p><p>Speaking at the same event, top U.S. infectious disease expert Anthony Fauci said there was no evidence that repeat booster doses would overwhelm the immune system.</p><p>&#34;Giving boosters at different times, there is really no evidence that&#39;s going to hinder (immune response).&#34;</p><p>Fauci said the goal should be to have a booster that induces a response against multiple potential variants.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna CEO says data for Omicron-specific shot likely available in March</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna CEO says data for Omicron-specific shot likely available in March\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-17 22:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/moderna-ceo-says-data-omicron-135958538.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Moderna Inc's vaccine candidate against the Omicron coronavirus variant will enter clinical development in the next few weeks and the company expects to be able to share data with regulators around ...</p>\n\n<a href=\"https://finance.yahoo.com/news/moderna-ceo-says-data-omicron-135958538.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4533":"AQR资本管理(全球第二大对冲基金)","BK4568":"美国抗疫概念","BNTX":"BioNTech SE","BK4532":"文艺复兴科技持仓","BK4551":"寇图资本持仓","BK4548":"巴美列捷福持仓","BK4535":"淡马锡持仓","MRNA":"Moderna, Inc.","BK4534":"瑞士信贷持仓","BK4139":"生物科技"},"source_url":"https://finance.yahoo.com/news/moderna-ceo-says-data-omicron-135958538.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2204577605","content_text":"Moderna Inc's vaccine candidate against the Omicron coronavirus variant will enter clinical development in the next few weeks and the company expects to be able to share data with regulators around March, CEO Stephane Bancel said on Monday.\"The vaccine is being finished ... it should be in the clinic in coming weeks. We are hoping in the March timeframe to be able to have data to share with regulators to figure out next steps,\" Bancel said at the World Economic Forum's virtual Davos Agenda conference.Moderna is also developing a single vaccine that combines a booster dose against COVID-19 with its experimental flu shot. ()Bancel said the best case scenario was the combined COVID/flu vaccine would be available by the fall of 2023, at least in some countries.\"Our goal is to be able to have a single annual booster so that we don't have compliance issues where people don't want to get two to three shots a winter.\"Many countries are already offering a third dose of a COVID-19 vaccine to their citizens, especially to older individuals and those who are immunocompromised, while Israel has started offering its citizens a fourth dose.Earlier in January, Moderna's CEO said people may need a fourth shot in the fall of 2022 as the efficacy of boosters against COVID-19 was likely to decline over the next few months.However, booster programs have met with skepticism from some disease experts over whether, and how widely, additional doses should become available, including the European Union's drug regulator, which has expressed doubts about the need for a fourth booster dose.Speaking at the same event, top U.S. infectious disease expert Anthony Fauci said there was no evidence that repeat booster doses would overwhelm the immune system.\"Giving boosters at different times, there is really no evidence that's going to hinder (immune response).\"Fauci said the goal should be to have a booster that induces a response against multiple potential variants.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9004022818,"gmtCreate":1642462416616,"gmtModify":1676533711844,"author":{"id":"4105527258434100","authorId":"4105527258434100","name":"HuatGirl","avatar":"https://community-static.tradeup.com/news/f4f221b60ade41caeefc225f39ab4105","vip":1,"crmLevel":1,"crmLevelSwitch":0},"htmlText":"Done&nbsp;","listText":"Done&nbsp;","text":"Done","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9004022818","repostId":2204577605,"repostType":4,"repost":{"id":"2204577605","pubTimestamp":1642431461,"share":"https://www.laohu8.com/m/news/2204577605?lang=&edition=full","pubTime":"2022-01-17 22:57","market":"us","language":"en","title":"Moderna CEO says data for Omicron-specific shot likely available in March","url":"https://stock-news.laohu8.com/highlight/detail?id=2204577605","media":"Reuters","summary":"Moderna Inc's vaccine candidate against the Omicron coronavirus variant will enter clinical developm","content":"<html><head></head><body><p>Moderna Inc&#39;s vaccine candidate against the Omicron coronavirus variant will enter clinical development in the next few weeks and the company expects to be able to share data with regulators around March, CEO Stephane Bancel said on Monday.</p><p>&#34;The vaccine is being finished ... it should be in the clinic in coming weeks. We are hoping in the March timeframe to be able to have data to share with regulators to figure out next steps,&#34; Bancel said at the World Economic Forum&#39;s virtual Davos Agenda conference.</p><p>Moderna is also developing a single vaccine that combines a booster dose against COVID-19 with its experimental flu shot. ()</p><p>Bancel said the best case scenario was the combined COVID/flu vaccine would be available by the fall of 2023, at least in some countries.</p><p>&#34;Our goal is to be able to have a single annual booster so that we don&#39;t have compliance issues where people don&#39;t want to get two to three shots a winter.&#34;</p><p>Many countries are already offering a third dose of a COVID-19 vaccine to their citizens, especially to older individuals and those who are immunocompromised, while Israel has started offering its citizens a fourth dose.</p><p>Earlier in January, Moderna&#39;s CEO said people may need a fourth shot in the fall of 2022 as the efficacy of boosters against COVID-19 was likely to decline over the next few months.</p><p>However, booster programs have met with skepticism from some disease experts over whether, and how widely, additional doses should become available, including the European Union&#39;s drug regulator, which has expressed doubts about the need for a fourth booster dose.</p><p>Speaking at the same event, top U.S. infectious disease expert Anthony Fauci said there was no evidence that repeat booster doses would overwhelm the immune system.</p><p>&#34;Giving boosters at different times, there is really no evidence that&#39;s going to hinder (immune response).&#34;</p><p>Fauci said the goal should be to have a booster that induces a response against multiple potential variants.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna CEO says data for Omicron-specific shot likely available in March</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna CEO says data for Omicron-specific shot likely available in March\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-17 22:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/moderna-ceo-says-data-omicron-135958538.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Moderna Inc's vaccine candidate against the Omicron coronavirus variant will enter clinical development in the next few weeks and the company expects to be able to share data with regulators around ...</p>\n\n<a href=\"https://finance.yahoo.com/news/moderna-ceo-says-data-omicron-135958538.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4533":"AQR资本管理(全球第二大对冲基金)","BK4568":"美国抗疫概念","BNTX":"BioNTech SE","BK4532":"文艺复兴科技持仓","BK4551":"寇图资本持仓","BK4548":"巴美列捷福持仓","BK4535":"淡马锡持仓","MRNA":"Moderna, Inc.","BK4534":"瑞士信贷持仓","BK4139":"生物科技"},"source_url":"https://finance.yahoo.com/news/moderna-ceo-says-data-omicron-135958538.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2204577605","content_text":"Moderna Inc's vaccine candidate against the Omicron coronavirus variant will enter clinical development in the next few weeks and the company expects to be able to share data with regulators around March, CEO Stephane Bancel said on Monday.\"The vaccine is being finished ... it should be in the clinic in coming weeks. We are hoping in the March timeframe to be able to have data to share with regulators to figure out next steps,\" Bancel said at the World Economic Forum's virtual Davos Agenda conference.Moderna is also developing a single vaccine that combines a booster dose against COVID-19 with its experimental flu shot. ()Bancel said the best case scenario was the combined COVID/flu vaccine would be available by the fall of 2023, at least in some countries.\"Our goal is to be able to have a single annual booster so that we don't have compliance issues where people don't want to get two to three shots a winter.\"Many countries are already offering a third dose of a COVID-19 vaccine to their citizens, especially to older individuals and those who are immunocompromised, while Israel has started offering its citizens a fourth dose.Earlier in January, Moderna's CEO said people may need a fourth shot in the fall of 2022 as the efficacy of boosters against COVID-19 was likely to decline over the next few months.However, booster programs have met with skepticism from some disease experts over whether, and how widely, additional doses should become available, including the European Union's drug regulator, which has expressed doubts about the need for a fourth booster dose.Speaking at the same event, top U.S. infectious disease expert Anthony Fauci said there was no evidence that repeat booster doses would overwhelm the immune system.\"Giving boosters at different times, there is really no evidence that's going to hinder (immune response).\"Fauci said the goal should be to have a booster that induces a response against multiple potential variants.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9004026313,"gmtCreate":1642462248225,"gmtModify":1676533711812,"author":{"id":"3557300951777174","authorId":"3557300951777174","name":"Pandachubby","avatar":"https://static.tigerbbs.com/4219cbe80202ef8b5c370a68f24f052b","vip":1,"crmLevel":6,"crmLevelSwitch":0},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9004026313","repostId":2204577605,"repostType":4,"repost":{"id":"2204577605","pubTimestamp":1642431461,"share":"https://www.laohu8.com/m/news/2204577605?lang=&edition=full","pubTime":"2022-01-17 22:57","market":"us","language":"en","title":"Moderna CEO says data for Omicron-specific shot likely available in March","url":"https://stock-news.laohu8.com/highlight/detail?id=2204577605","media":"Reuters","summary":"Moderna Inc's vaccine candidate against the Omicron coronavirus variant will enter clinical developm","content":"<html><head></head><body><p>Moderna Inc&#39;s vaccine candidate against the Omicron coronavirus variant will enter clinical development in the next few weeks and the company expects to be able to share data with regulators around March, CEO Stephane Bancel said on Monday.</p><p>&#34;The vaccine is being finished ... it should be in the clinic in coming weeks. We are hoping in the March timeframe to be able to have data to share with regulators to figure out next steps,&#34; Bancel said at the World Economic Forum&#39;s virtual Davos Agenda conference.</p><p>Moderna is also developing a single vaccine that combines a booster dose against COVID-19 with its experimental flu shot. ()</p><p>Bancel said the best case scenario was the combined COVID/flu vaccine would be available by the fall of 2023, at least in some countries.</p><p>&#34;Our goal is to be able to have a single annual booster so that we don&#39;t have compliance issues where people don&#39;t want to get two to three shots a winter.&#34;</p><p>Many countries are already offering a third dose of a COVID-19 vaccine to their citizens, especially to older individuals and those who are immunocompromised, while Israel has started offering its citizens a fourth dose.</p><p>Earlier in January, Moderna&#39;s CEO said people may need a fourth shot in the fall of 2022 as the efficacy of boosters against COVID-19 was likely to decline over the next few months.</p><p>However, booster programs have met with skepticism from some disease experts over whether, and how widely, additional doses should become available, including the European Union&#39;s drug regulator, which has expressed doubts about the need for a fourth booster dose.</p><p>Speaking at the same event, top U.S. infectious disease expert Anthony Fauci said there was no evidence that repeat booster doses would overwhelm the immune system.</p><p>&#34;Giving boosters at different times, there is really no evidence that&#39;s going to hinder (immune response).&#34;</p><p>Fauci said the goal should be to have a booster that induces a response against multiple potential variants.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna CEO says data for Omicron-specific shot likely available in March</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna CEO says data for Omicron-specific shot likely available in March\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-17 22:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/moderna-ceo-says-data-omicron-135958538.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Moderna Inc's vaccine candidate against the Omicron coronavirus variant will enter clinical development in the next few weeks and the company expects to be able to share data with regulators around ...</p>\n\n<a href=\"https://finance.yahoo.com/news/moderna-ceo-says-data-omicron-135958538.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4533":"AQR资本管理(全球第二大对冲基金)","BK4568":"美国抗疫概念","BNTX":"BioNTech SE","BK4532":"文艺复兴科技持仓","BK4551":"寇图资本持仓","BK4548":"巴美列捷福持仓","BK4535":"淡马锡持仓","MRNA":"Moderna, Inc.","BK4534":"瑞士信贷持仓","BK4139":"生物科技"},"source_url":"https://finance.yahoo.com/news/moderna-ceo-says-data-omicron-135958538.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2204577605","content_text":"Moderna Inc's vaccine candidate against the Omicron coronavirus variant will enter clinical development in the next few weeks and the company expects to be able to share data with regulators around March, CEO Stephane Bancel said on Monday.\"The vaccine is being finished ... it should be in the clinic in coming weeks. We are hoping in the March timeframe to be able to have data to share with regulators to figure out next steps,\" Bancel said at the World Economic Forum's virtual Davos Agenda conference.Moderna is also developing a single vaccine that combines a booster dose against COVID-19 with its experimental flu shot. ()Bancel said the best case scenario was the combined COVID/flu vaccine would be available by the fall of 2023, at least in some countries.\"Our goal is to be able to have a single annual booster so that we don't have compliance issues where people don't want to get two to three shots a winter.\"Many countries are already offering a third dose of a COVID-19 vaccine to their citizens, especially to older individuals and those who are immunocompromised, while Israel has started offering its citizens a fourth dose.Earlier in January, Moderna's CEO said people may need a fourth shot in the fall of 2022 as the efficacy of boosters against COVID-19 was likely to decline over the next few months.However, booster programs have met with skepticism from some disease experts over whether, and how widely, additional doses should become available, including the European Union's drug regulator, which has expressed doubts about the need for a fourth booster dose.Speaking at the same event, top U.S. infectious disease expert Anthony Fauci said there was no evidence that repeat booster doses would overwhelm the immune system.\"Giving boosters at different times, there is really no evidence that's going to hinder (immune response).\"Fauci said the goal should be to have a booster that induces a response against multiple potential variants.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9004020549,"gmtCreate":1642461583883,"gmtModify":1676533711712,"author":{"id":"3585190346107555","authorId":"3585190346107555","name":"WindyMoon","avatar":"https://static.tigerbbs.com/8e3e8fe6ed7167969540d7d4434286db","vip":1,"hat":"https://static.tigerbbs.com/b073a07f77dbe6b3bec6b12311fde6bd","crmLevel":2,"crmLevelSwitch":1},"htmlText":"[Cool]&nbsp;","listText":"[Cool]&nbsp;","text":"[Cool]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9004020549","repostId":2204577605,"repostType":4,"repost":{"id":"2204577605","pubTimestamp":1642431461,"share":"https://www.laohu8.com/m/news/2204577605?lang=&edition=full","pubTime":"2022-01-17 22:57","market":"us","language":"en","title":"Moderna CEO says data for Omicron-specific shot likely available in March","url":"https://stock-news.laohu8.com/highlight/detail?id=2204577605","media":"Reuters","summary":"Moderna Inc's vaccine candidate against the Omicron coronavirus variant will enter clinical developm","content":"<html><head></head><body><p>Moderna Inc&#39;s vaccine candidate against the Omicron coronavirus variant will enter clinical development in the next few weeks and the company expects to be able to share data with regulators around March, CEO Stephane Bancel said on Monday.</p><p>&#34;The vaccine is being finished ... it should be in the clinic in coming weeks. We are hoping in the March timeframe to be able to have data to share with regulators to figure out next steps,&#34; Bancel said at the World Economic Forum&#39;s virtual Davos Agenda conference.</p><p>Moderna is also developing a single vaccine that combines a booster dose against COVID-19 with its experimental flu shot. ()</p><p>Bancel said the best case scenario was the combined COVID/flu vaccine would be available by the fall of 2023, at least in some countries.</p><p>&#34;Our goal is to be able to have a single annual booster so that we don&#39;t have compliance issues where people don&#39;t want to get two to three shots a winter.&#34;</p><p>Many countries are already offering a third dose of a COVID-19 vaccine to their citizens, especially to older individuals and those who are immunocompromised, while Israel has started offering its citizens a fourth dose.</p><p>Earlier in January, Moderna&#39;s CEO said people may need a fourth shot in the fall of 2022 as the efficacy of boosters against COVID-19 was likely to decline over the next few months.</p><p>However, booster programs have met with skepticism from some disease experts over whether, and how widely, additional doses should become available, including the European Union&#39;s drug regulator, which has expressed doubts about the need for a fourth booster dose.</p><p>Speaking at the same event, top U.S. infectious disease expert Anthony Fauci said there was no evidence that repeat booster doses would overwhelm the immune system.</p><p>&#34;Giving boosters at different times, there is really no evidence that&#39;s going to hinder (immune response).&#34;</p><p>Fauci said the goal should be to have a booster that induces a response against multiple potential variants.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna CEO says data for Omicron-specific shot likely available in March</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna CEO says data for Omicron-specific shot likely available in March\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-17 22:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/moderna-ceo-says-data-omicron-135958538.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Moderna Inc's vaccine candidate against the Omicron coronavirus variant will enter clinical development in the next few weeks and the company expects to be able to share data with regulators around ...</p>\n\n<a href=\"https://finance.yahoo.com/news/moderna-ceo-says-data-omicron-135958538.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4533":"AQR资本管理(全球第二大对冲基金)","BK4568":"美国抗疫概念","BNTX":"BioNTech SE","BK4532":"文艺复兴科技持仓","BK4551":"寇图资本持仓","BK4548":"巴美列捷福持仓","BK4535":"淡马锡持仓","MRNA":"Moderna, Inc.","BK4534":"瑞士信贷持仓","BK4139":"生物科技"},"source_url":"https://finance.yahoo.com/news/moderna-ceo-says-data-omicron-135958538.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2204577605","content_text":"Moderna Inc's vaccine candidate against the Omicron coronavirus variant will enter clinical development in the next few weeks and the company expects to be able to share data with regulators around March, CEO Stephane Bancel said on Monday.\"The vaccine is being finished ... it should be in the clinic in coming weeks. We are hoping in the March timeframe to be able to have data to share with regulators to figure out next steps,\" Bancel said at the World Economic Forum's virtual Davos Agenda conference.Moderna is also developing a single vaccine that combines a booster dose against COVID-19 with its experimental flu shot. ()Bancel said the best case scenario was the combined COVID/flu vaccine would be available by the fall of 2023, at least in some countries.\"Our goal is to be able to have a single annual booster so that we don't have compliance issues where people don't want to get two to three shots a winter.\"Many countries are already offering a third dose of a COVID-19 vaccine to their citizens, especially to older individuals and those who are immunocompromised, while Israel has started offering its citizens a fourth dose.Earlier in January, Moderna's CEO said people may need a fourth shot in the fall of 2022 as the efficacy of boosters against COVID-19 was likely to decline over the next few months.However, booster programs have met with skepticism from some disease experts over whether, and how widely, additional doses should become available, including the European Union's drug regulator, which has expressed doubts about the need for a fourth booster dose.Speaking at the same event, top U.S. infectious disease expert Anthony Fauci said there was no evidence that repeat booster doses would overwhelm the immune system.\"Giving boosters at different times, there is really no evidence that's going to hinder (immune response).\"Fauci said the goal should be to have a booster that induces a response against multiple potential variants.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9004020316,"gmtCreate":1642461529365,"gmtModify":1676533711696,"author":{"id":"4098445225447010","authorId":"4098445225447010","name":"Ah Deck","avatar":"https://static.tigerbbs.com/0e52eb1e14e0f630d24f1687ea546cd8","vip":1,"crmLevel":3,"crmLevelSwitch":1},"htmlText":"Pls like&nbsp;","listText":"Pls like&nbsp;","text":"Pls like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9004020316","repostId":2204577605,"repostType":4,"repost":{"id":"2204577605","pubTimestamp":1642431461,"share":"https://www.laohu8.com/m/news/2204577605?lang=&edition=full","pubTime":"2022-01-17 22:57","market":"us","language":"en","title":"Moderna CEO says data for Omicron-specific shot likely available in March","url":"https://stock-news.laohu8.com/highlight/detail?id=2204577605","media":"Reuters","summary":"Moderna Inc's vaccine candidate against the Omicron coronavirus variant will enter clinical developm","content":"<html><head></head><body><p>Moderna Inc&#39;s vaccine candidate against the Omicron coronavirus variant will enter clinical development in the next few weeks and the company expects to be able to share data with regulators around March, CEO Stephane Bancel said on Monday.</p><p>&#34;The vaccine is being finished ... it should be in the clinic in coming weeks. We are hoping in the March timeframe to be able to have data to share with regulators to figure out next steps,&#34; Bancel said at the World Economic Forum&#39;s virtual Davos Agenda conference.</p><p>Moderna is also developing a single vaccine that combines a booster dose against COVID-19 with its experimental flu shot. ()</p><p>Bancel said the best case scenario was the combined COVID/flu vaccine would be available by the fall of 2023, at least in some countries.</p><p>&#34;Our goal is to be able to have a single annual booster so that we don&#39;t have compliance issues where people don&#39;t want to get two to three shots a winter.&#34;</p><p>Many countries are already offering a third dose of a COVID-19 vaccine to their citizens, especially to older individuals and those who are immunocompromised, while Israel has started offering its citizens a fourth dose.</p><p>Earlier in January, Moderna&#39;s CEO said people may need a fourth shot in the fall of 2022 as the efficacy of boosters against COVID-19 was likely to decline over the next few months.</p><p>However, booster programs have met with skepticism from some disease experts over whether, and how widely, additional doses should become available, including the European Union&#39;s drug regulator, which has expressed doubts about the need for a fourth booster dose.</p><p>Speaking at the same event, top U.S. infectious disease expert Anthony Fauci said there was no evidence that repeat booster doses would overwhelm the immune system.</p><p>&#34;Giving boosters at different times, there is really no evidence that&#39;s going to hinder (immune response).&#34;</p><p>Fauci said the goal should be to have a booster that induces a response against multiple potential variants.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna CEO says data for Omicron-specific shot likely available in March</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna CEO says data for Omicron-specific shot likely available in March\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-17 22:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/moderna-ceo-says-data-omicron-135958538.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Moderna Inc's vaccine candidate against the Omicron coronavirus variant will enter clinical development in the next few weeks and the company expects to be able to share data with regulators around ...</p>\n\n<a href=\"https://finance.yahoo.com/news/moderna-ceo-says-data-omicron-135958538.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4533":"AQR资本管理(全球第二大对冲基金)","BK4568":"美国抗疫概念","BNTX":"BioNTech SE","BK4532":"文艺复兴科技持仓","BK4551":"寇图资本持仓","BK4548":"巴美列捷福持仓","BK4535":"淡马锡持仓","MRNA":"Moderna, Inc.","BK4534":"瑞士信贷持仓","BK4139":"生物科技"},"source_url":"https://finance.yahoo.com/news/moderna-ceo-says-data-omicron-135958538.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2204577605","content_text":"Moderna Inc's vaccine candidate against the Omicron coronavirus variant will enter clinical development in the next few weeks and the company expects to be able to share data with regulators around March, CEO Stephane Bancel said on Monday.\"The vaccine is being finished ... it should be in the clinic in coming weeks. We are hoping in the March timeframe to be able to have data to share with regulators to figure out next steps,\" Bancel said at the World Economic Forum's virtual Davos Agenda conference.Moderna is also developing a single vaccine that combines a booster dose against COVID-19 with its experimental flu shot. ()Bancel said the best case scenario was the combined COVID/flu vaccine would be available by the fall of 2023, at least in some countries.\"Our goal is to be able to have a single annual booster so that we don't have compliance issues where people don't want to get two to three shots a winter.\"Many countries are already offering a third dose of a COVID-19 vaccine to their citizens, especially to older individuals and those who are immunocompromised, while Israel has started offering its citizens a fourth dose.Earlier in January, Moderna's CEO said people may need a fourth shot in the fall of 2022 as the efficacy of boosters against COVID-19 was likely to decline over the next few months.However, booster programs have met with skepticism from some disease experts over whether, and how widely, additional doses should become available, including the European Union's drug regulator, which has expressed doubts about the need for a fourth booster dose.Speaking at the same event, top U.S. infectious disease expert Anthony Fauci said there was no evidence that repeat booster doses would overwhelm the immune system.\"Giving boosters at different times, there is really no evidence that's going to hinder (immune response).\"Fauci said the goal should be to have a booster that induces a response against multiple potential variants.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9004020153,"gmtCreate":1642461529339,"gmtModify":1676533711696,"author":{"id":"3582709211377801","authorId":"3582709211377801","name":"LameDude","avatar":"https://static.tigerbbs.com/1fad169ba882e7ecc17ccafb3bf4ecaf","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9004020153","repostId":2204577605,"repostType":4,"repost":{"id":"2204577605","pubTimestamp":1642431461,"share":"https://www.laohu8.com/m/news/2204577605?lang=&edition=full","pubTime":"2022-01-17 22:57","market":"us","language":"en","title":"Moderna CEO says data for Omicron-specific shot likely available in March","url":"https://stock-news.laohu8.com/highlight/detail?id=2204577605","media":"Reuters","summary":"Moderna Inc's vaccine candidate against the Omicron coronavirus variant will enter clinical developm","content":"<html><head></head><body><p>Moderna Inc&#39;s vaccine candidate against the Omicron coronavirus variant will enter clinical development in the next few weeks and the company expects to be able to share data with regulators around March, CEO Stephane Bancel said on Monday.</p><p>&#34;The vaccine is being finished ... it should be in the clinic in coming weeks. We are hoping in the March timeframe to be able to have data to share with regulators to figure out next steps,&#34; Bancel said at the World Economic Forum&#39;s virtual Davos Agenda conference.</p><p>Moderna is also developing a single vaccine that combines a booster dose against COVID-19 with its experimental flu shot. ()</p><p>Bancel said the best case scenario was the combined COVID/flu vaccine would be available by the fall of 2023, at least in some countries.</p><p>&#34;Our goal is to be able to have a single annual booster so that we don&#39;t have compliance issues where people don&#39;t want to get two to three shots a winter.&#34;</p><p>Many countries are already offering a third dose of a COVID-19 vaccine to their citizens, especially to older individuals and those who are immunocompromised, while Israel has started offering its citizens a fourth dose.</p><p>Earlier in January, Moderna&#39;s CEO said people may need a fourth shot in the fall of 2022 as the efficacy of boosters against COVID-19 was likely to decline over the next few months.</p><p>However, booster programs have met with skepticism from some disease experts over whether, and how widely, additional doses should become available, including the European Union&#39;s drug regulator, which has expressed doubts about the need for a fourth booster dose.</p><p>Speaking at the same event, top U.S. infectious disease expert Anthony Fauci said there was no evidence that repeat booster doses would overwhelm the immune system.</p><p>&#34;Giving boosters at different times, there is really no evidence that&#39;s going to hinder (immune response).&#34;</p><p>Fauci said the goal should be to have a booster that induces a response against multiple potential variants.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna CEO says data for Omicron-specific shot likely available in March</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna CEO says data for Omicron-specific shot likely available in March\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-17 22:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/moderna-ceo-says-data-omicron-135958538.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Moderna Inc's vaccine candidate against the Omicron coronavirus variant will enter clinical development in the next few weeks and the company expects to be able to share data with regulators around ...</p>\n\n<a href=\"https://finance.yahoo.com/news/moderna-ceo-says-data-omicron-135958538.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4533":"AQR资本管理(全球第二大对冲基金)","BK4568":"美国抗疫概念","BNTX":"BioNTech SE","BK4532":"文艺复兴科技持仓","BK4551":"寇图资本持仓","BK4548":"巴美列捷福持仓","BK4535":"淡马锡持仓","MRNA":"Moderna, Inc.","BK4534":"瑞士信贷持仓","BK4139":"生物科技"},"source_url":"https://finance.yahoo.com/news/moderna-ceo-says-data-omicron-135958538.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2204577605","content_text":"Moderna Inc's vaccine candidate against the Omicron coronavirus variant will enter clinical development in the next few weeks and the company expects to be able to share data with regulators around March, CEO Stephane Bancel said on Monday.\"The vaccine is being finished ... it should be in the clinic in coming weeks. We are hoping in the March timeframe to be able to have data to share with regulators to figure out next steps,\" Bancel said at the World Economic Forum's virtual Davos Agenda conference.Moderna is also developing a single vaccine that combines a booster dose against COVID-19 with its experimental flu shot. ()Bancel said the best case scenario was the combined COVID/flu vaccine would be available by the fall of 2023, at least in some countries.\"Our goal is to be able to have a single annual booster so that we don't have compliance issues where people don't want to get two to three shots a winter.\"Many countries are already offering a third dose of a COVID-19 vaccine to their citizens, especially to older individuals and those who are immunocompromised, while Israel has started offering its citizens a fourth dose.Earlier in January, Moderna's CEO said people may need a fourth shot in the fall of 2022 as the efficacy of boosters against COVID-19 was likely to decline over the next few months.However, booster programs have met with skepticism from some disease experts over whether, and how widely, additional doses should become available, including the European Union's drug regulator, which has expressed doubts about the need for a fourth booster dose.Speaking at the same event, top U.S. infectious disease expert Anthony Fauci said there was no evidence that repeat booster doses would overwhelm the immune system.\"Giving boosters at different times, there is really no evidence that's going to hinder (immune response).\"Fauci said the goal should be to have a booster that induces a response against multiple potential variants.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9004067480,"gmtCreate":1642461474569,"gmtModify":1676533711704,"author":{"id":"4101948424484190","authorId":"4101948424484190","name":"Success88","avatar":"https://static.itradeup.com/news/4408e1a22d73e99adb53aa65dde8ad91","vip":1,"hat":"https://static.tigerbbs.com/b0a2963eb37c60c5d6d4a8dbcd266952","crmLevel":3,"crmLevelSwitch":0},"htmlText":"Yeah&nbsp;","listText":"Yeah&nbsp;","text":"Yeah","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9004067480","repostId":2204577605,"repostType":4,"repost":{"id":"2204577605","pubTimestamp":1642431461,"share":"https://www.laohu8.com/m/news/2204577605?lang=&edition=full","pubTime":"2022-01-17 22:57","market":"us","language":"en","title":"Moderna CEO says data for Omicron-specific shot likely available in March","url":"https://stock-news.laohu8.com/highlight/detail?id=2204577605","media":"Reuters","summary":"Moderna Inc's vaccine candidate against the Omicron coronavirus variant will enter clinical developm","content":"<html><head></head><body><p>Moderna Inc&#39;s vaccine candidate against the Omicron coronavirus variant will enter clinical development in the next few weeks and the company expects to be able to share data with regulators around March, CEO Stephane Bancel said on Monday.</p><p>&#34;The vaccine is being finished ... it should be in the clinic in coming weeks. We are hoping in the March timeframe to be able to have data to share with regulators to figure out next steps,&#34; Bancel said at the World Economic Forum&#39;s virtual Davos Agenda conference.</p><p>Moderna is also developing a single vaccine that combines a booster dose against COVID-19 with its experimental flu shot. ()</p><p>Bancel said the best case scenario was the combined COVID/flu vaccine would be available by the fall of 2023, at least in some countries.</p><p>&#34;Our goal is to be able to have a single annual booster so that we don&#39;t have compliance issues where people don&#39;t want to get two to three shots a winter.&#34;</p><p>Many countries are already offering a third dose of a COVID-19 vaccine to their citizens, especially to older individuals and those who are immunocompromised, while Israel has started offering its citizens a fourth dose.</p><p>Earlier in January, Moderna&#39;s CEO said people may need a fourth shot in the fall of 2022 as the efficacy of boosters against COVID-19 was likely to decline over the next few months.</p><p>However, booster programs have met with skepticism from some disease experts over whether, and how widely, additional doses should become available, including the European Union&#39;s drug regulator, which has expressed doubts about the need for a fourth booster dose.</p><p>Speaking at the same event, top U.S. infectious disease expert Anthony Fauci said there was no evidence that repeat booster doses would overwhelm the immune system.</p><p>&#34;Giving boosters at different times, there is really no evidence that&#39;s going to hinder (immune response).&#34;</p><p>Fauci said the goal should be to have a booster that induces a response against multiple potential variants.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna CEO says data for Omicron-specific shot likely available in March</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna CEO says data for Omicron-specific shot likely available in March\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-17 22:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/moderna-ceo-says-data-omicron-135958538.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Moderna Inc's vaccine candidate against the Omicron coronavirus variant will enter clinical development in the next few weeks and the company expects to be able to share data with regulators around ...</p>\n\n<a href=\"https://finance.yahoo.com/news/moderna-ceo-says-data-omicron-135958538.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4533":"AQR资本管理(全球第二大对冲基金)","BK4568":"美国抗疫概念","BNTX":"BioNTech SE","BK4532":"文艺复兴科技持仓","BK4551":"寇图资本持仓","BK4548":"巴美列捷福持仓","BK4535":"淡马锡持仓","MRNA":"Moderna, Inc.","BK4534":"瑞士信贷持仓","BK4139":"生物科技"},"source_url":"https://finance.yahoo.com/news/moderna-ceo-says-data-omicron-135958538.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2204577605","content_text":"Moderna Inc's vaccine candidate against the Omicron coronavirus variant will enter clinical development in the next few weeks and the company expects to be able to share data with regulators around March, CEO Stephane Bancel said on Monday.\"The vaccine is being finished ... it should be in the clinic in coming weeks. We are hoping in the March timeframe to be able to have data to share with regulators to figure out next steps,\" Bancel said at the World Economic Forum's virtual Davos Agenda conference.Moderna is also developing a single vaccine that combines a booster dose against COVID-19 with its experimental flu shot. ()Bancel said the best case scenario was the combined COVID/flu vaccine would be available by the fall of 2023, at least in some countries.\"Our goal is to be able to have a single annual booster so that we don't have compliance issues where people don't want to get two to three shots a winter.\"Many countries are already offering a third dose of a COVID-19 vaccine to their citizens, especially to older individuals and those who are immunocompromised, while Israel has started offering its citizens a fourth dose.Earlier in January, Moderna's CEO said people may need a fourth shot in the fall of 2022 as the efficacy of boosters against COVID-19 was likely to decline over the next few months.However, booster programs have met with skepticism from some disease experts over whether, and how widely, additional doses should become available, including the European Union's drug regulator, which has expressed doubts about the need for a fourth booster dose.Speaking at the same event, top U.S. infectious disease expert Anthony Fauci said there was no evidence that repeat booster doses would overwhelm the immune system.\"Giving boosters at different times, there is really no evidence that's going to hinder (immune response).\"Fauci said the goal should be to have a booster that induces a response against multiple potential variants.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9004067295,"gmtCreate":1642461452442,"gmtModify":1676533711680,"author":{"id":"4099464847810740","authorId":"4099464847810740","name":"Tyanak","avatar":"https://static.tigerbbs.com/06395489130b165c03280007e704e978","vip":1,"crmLevel":2,"crmLevelSwitch":1},"htmlText":"👍🏻","listText":"👍🏻","text":"👍🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9004067295","repostId":2204577605,"repostType":4,"repost":{"id":"2204577605","pubTimestamp":1642431461,"share":"https://www.laohu8.com/m/news/2204577605?lang=&edition=full","pubTime":"2022-01-17 22:57","market":"us","language":"en","title":"Moderna CEO says data for Omicron-specific shot likely available in March","url":"https://stock-news.laohu8.com/highlight/detail?id=2204577605","media":"Reuters","summary":"Moderna Inc's vaccine candidate against the Omicron coronavirus variant will enter clinical developm","content":"<html><head></head><body><p>Moderna Inc&#39;s vaccine candidate against the Omicron coronavirus variant will enter clinical development in the next few weeks and the company expects to be able to share data with regulators around March, CEO Stephane Bancel said on Monday.</p><p>&#34;The vaccine is being finished ... it should be in the clinic in coming weeks. We are hoping in the March timeframe to be able to have data to share with regulators to figure out next steps,&#34; Bancel said at the World Economic Forum&#39;s virtual Davos Agenda conference.</p><p>Moderna is also developing a single vaccine that combines a booster dose against COVID-19 with its experimental flu shot. ()</p><p>Bancel said the best case scenario was the combined COVID/flu vaccine would be available by the fall of 2023, at least in some countries.</p><p>&#34;Our goal is to be able to have a single annual booster so that we don&#39;t have compliance issues where people don&#39;t want to get two to three shots a winter.&#34;</p><p>Many countries are already offering a third dose of a COVID-19 vaccine to their citizens, especially to older individuals and those who are immunocompromised, while Israel has started offering its citizens a fourth dose.</p><p>Earlier in January, Moderna&#39;s CEO said people may need a fourth shot in the fall of 2022 as the efficacy of boosters against COVID-19 was likely to decline over the next few months.</p><p>However, booster programs have met with skepticism from some disease experts over whether, and how widely, additional doses should become available, including the European Union&#39;s drug regulator, which has expressed doubts about the need for a fourth booster dose.</p><p>Speaking at the same event, top U.S. infectious disease expert Anthony Fauci said there was no evidence that repeat booster doses would overwhelm the immune system.</p><p>&#34;Giving boosters at different times, there is really no evidence that&#39;s going to hinder (immune response).&#34;</p><p>Fauci said the goal should be to have a booster that induces a response against multiple potential variants.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna CEO says data for Omicron-specific shot likely available in March</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna CEO says data for Omicron-specific shot likely available in March\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-17 22:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/moderna-ceo-says-data-omicron-135958538.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Moderna Inc's vaccine candidate against the Omicron coronavirus variant will enter clinical development in the next few weeks and the company expects to be able to share data with regulators around ...</p>\n\n<a href=\"https://finance.yahoo.com/news/moderna-ceo-says-data-omicron-135958538.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4533":"AQR资本管理(全球第二大对冲基金)","BK4568":"美国抗疫概念","BNTX":"BioNTech SE","BK4532":"文艺复兴科技持仓","BK4551":"寇图资本持仓","BK4548":"巴美列捷福持仓","BK4535":"淡马锡持仓","MRNA":"Moderna, Inc.","BK4534":"瑞士信贷持仓","BK4139":"生物科技"},"source_url":"https://finance.yahoo.com/news/moderna-ceo-says-data-omicron-135958538.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2204577605","content_text":"Moderna Inc's vaccine candidate against the Omicron coronavirus variant will enter clinical development in the next few weeks and the company expects to be able to share data with regulators around March, CEO Stephane Bancel said on Monday.\"The vaccine is being finished ... it should be in the clinic in coming weeks. We are hoping in the March timeframe to be able to have data to share with regulators to figure out next steps,\" Bancel said at the World Economic Forum's virtual Davos Agenda conference.Moderna is also developing a single vaccine that combines a booster dose against COVID-19 with its experimental flu shot. ()Bancel said the best case scenario was the combined COVID/flu vaccine would be available by the fall of 2023, at least in some countries.\"Our goal is to be able to have a single annual booster so that we don't have compliance issues where people don't want to get two to three shots a winter.\"Many countries are already offering a third dose of a COVID-19 vaccine to their citizens, especially to older individuals and those who are immunocompromised, while Israel has started offering its citizens a fourth dose.Earlier in January, Moderna's CEO said people may need a fourth shot in the fall of 2022 as the efficacy of boosters against COVID-19 was likely to decline over the next few months.However, booster programs have met with skepticism from some disease experts over whether, and how widely, additional doses should become available, including the European Union's drug regulator, which has expressed doubts about the need for a fourth booster dose.Speaking at the same event, top U.S. infectious disease expert Anthony Fauci said there was no evidence that repeat booster doses would overwhelm the immune system.\"Giving boosters at different times, there is really no evidence that's going to hinder (immune response).\"Fauci said the goal should be to have a booster that induces a response against multiple potential variants.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9004064398,"gmtCreate":1642461354614,"gmtModify":1676533711649,"author":{"id":"4094787464285000","authorId":"4094787464285000","name":"whitesnake","avatar":"https://static.tigerbbs.com/86038a40c72380b34bced828cc9422b2","vip":1,"crmLevel":5,"crmLevelSwitch":0},"htmlText":"👍🏻","listText":"👍🏻","text":"👍🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9004064398","repostId":2204577605,"repostType":4,"repost":{"id":"2204577605","pubTimestamp":1642431461,"share":"https://www.laohu8.com/m/news/2204577605?lang=&edition=full","pubTime":"2022-01-17 22:57","market":"us","language":"en","title":"Moderna CEO says data for Omicron-specific shot likely available in March","url":"https://stock-news.laohu8.com/highlight/detail?id=2204577605","media":"Reuters","summary":"Moderna Inc's vaccine candidate against the Omicron coronavirus variant will enter clinical developm","content":"<html><head></head><body><p>Moderna Inc&#39;s vaccine candidate against the Omicron coronavirus variant will enter clinical development in the next few weeks and the company expects to be able to share data with regulators around March, CEO Stephane Bancel said on Monday.</p><p>&#34;The vaccine is being finished ... it should be in the clinic in coming weeks. We are hoping in the March timeframe to be able to have data to share with regulators to figure out next steps,&#34; Bancel said at the World Economic Forum&#39;s virtual Davos Agenda conference.</p><p>Moderna is also developing a single vaccine that combines a booster dose against COVID-19 with its experimental flu shot. ()</p><p>Bancel said the best case scenario was the combined COVID/flu vaccine would be available by the fall of 2023, at least in some countries.</p><p>&#34;Our goal is to be able to have a single annual booster so that we don&#39;t have compliance issues where people don&#39;t want to get two to three shots a winter.&#34;</p><p>Many countries are already offering a third dose of a COVID-19 vaccine to their citizens, especially to older individuals and those who are immunocompromised, while Israel has started offering its citizens a fourth dose.</p><p>Earlier in January, Moderna&#39;s CEO said people may need a fourth shot in the fall of 2022 as the efficacy of boosters against COVID-19 was likely to decline over the next few months.</p><p>However, booster programs have met with skepticism from some disease experts over whether, and how widely, additional doses should become available, including the European Union&#39;s drug regulator, which has expressed doubts about the need for a fourth booster dose.</p><p>Speaking at the same event, top U.S. infectious disease expert Anthony Fauci said there was no evidence that repeat booster doses would overwhelm the immune system.</p><p>&#34;Giving boosters at different times, there is really no evidence that&#39;s going to hinder (immune response).&#34;</p><p>Fauci said the goal should be to have a booster that induces a response against multiple potential variants.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna CEO says data for Omicron-specific shot likely available in March</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna CEO says data for Omicron-specific shot likely available in March\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-17 22:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/moderna-ceo-says-data-omicron-135958538.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Moderna Inc's vaccine candidate against the Omicron coronavirus variant will enter clinical development in the next few weeks and the company expects to be able to share data with regulators around ...</p>\n\n<a href=\"https://finance.yahoo.com/news/moderna-ceo-says-data-omicron-135958538.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4533":"AQR资本管理(全球第二大对冲基金)","BK4568":"美国抗疫概念","BNTX":"BioNTech SE","BK4532":"文艺复兴科技持仓","BK4551":"寇图资本持仓","BK4548":"巴美列捷福持仓","BK4535":"淡马锡持仓","MRNA":"Moderna, Inc.","BK4534":"瑞士信贷持仓","BK4139":"生物科技"},"source_url":"https://finance.yahoo.com/news/moderna-ceo-says-data-omicron-135958538.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2204577605","content_text":"Moderna Inc's vaccine candidate against the Omicron coronavirus variant will enter clinical development in the next few weeks and the company expects to be able to share data with regulators around March, CEO Stephane Bancel said on Monday.\"The vaccine is being finished ... it should be in the clinic in coming weeks. We are hoping in the March timeframe to be able to have data to share with regulators to figure out next steps,\" Bancel said at the World Economic Forum's virtual Davos Agenda conference.Moderna is also developing a single vaccine that combines a booster dose against COVID-19 with its experimental flu shot. ()Bancel said the best case scenario was the combined COVID/flu vaccine would be available by the fall of 2023, at least in some countries.\"Our goal is to be able to have a single annual booster so that we don't have compliance issues where people don't want to get two to three shots a winter.\"Many countries are already offering a third dose of a COVID-19 vaccine to their citizens, especially to older individuals and those who are immunocompromised, while Israel has started offering its citizens a fourth dose.Earlier in January, Moderna's CEO said people may need a fourth shot in the fall of 2022 as the efficacy of boosters against COVID-19 was likely to decline over the next few months.However, booster programs have met with skepticism from some disease experts over whether, and how widely, additional doses should become available, including the European Union's drug regulator, which has expressed doubts about the need for a fourth booster dose.Speaking at the same event, top U.S. infectious disease expert Anthony Fauci said there was no evidence that repeat booster doses would overwhelm the immune system.\"Giving boosters at different times, there is really no evidence that's going to hinder (immune response).\"Fauci said the goal should be to have a booster that induces a response against multiple potential variants.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9004064953,"gmtCreate":1642461307545,"gmtModify":1676533711649,"author":{"id":"4098273802374380","authorId":"4098273802374380","name":"SiewMailing","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9004064953","repostId":2204577605,"repostType":4,"repost":{"id":"2204577605","pubTimestamp":1642431461,"share":"https://www.laohu8.com/m/news/2204577605?lang=&edition=full","pubTime":"2022-01-17 22:57","market":"us","language":"en","title":"Moderna CEO says data for Omicron-specific shot likely available in March","url":"https://stock-news.laohu8.com/highlight/detail?id=2204577605","media":"Reuters","summary":"Moderna Inc's vaccine candidate against the Omicron coronavirus variant will enter clinical developm","content":"<html><head></head><body><p>Moderna Inc&#39;s vaccine candidate against the Omicron coronavirus variant will enter clinical development in the next few weeks and the company expects to be able to share data with regulators around March, CEO Stephane Bancel said on Monday.</p><p>&#34;The vaccine is being finished ... it should be in the clinic in coming weeks. We are hoping in the March timeframe to be able to have data to share with regulators to figure out next steps,&#34; Bancel said at the World Economic Forum&#39;s virtual Davos Agenda conference.</p><p>Moderna is also developing a single vaccine that combines a booster dose against COVID-19 with its experimental flu shot. ()</p><p>Bancel said the best case scenario was the combined COVID/flu vaccine would be available by the fall of 2023, at least in some countries.</p><p>&#34;Our goal is to be able to have a single annual booster so that we don&#39;t have compliance issues where people don&#39;t want to get two to three shots a winter.&#34;</p><p>Many countries are already offering a third dose of a COVID-19 vaccine to their citizens, especially to older individuals and those who are immunocompromised, while Israel has started offering its citizens a fourth dose.</p><p>Earlier in January, Moderna&#39;s CEO said people may need a fourth shot in the fall of 2022 as the efficacy of boosters against COVID-19 was likely to decline over the next few months.</p><p>However, booster programs have met with skepticism from some disease experts over whether, and how widely, additional doses should become available, including the European Union&#39;s drug regulator, which has expressed doubts about the need for a fourth booster dose.</p><p>Speaking at the same event, top U.S. infectious disease expert Anthony Fauci said there was no evidence that repeat booster doses would overwhelm the immune system.</p><p>&#34;Giving boosters at different times, there is really no evidence that&#39;s going to hinder (immune response).&#34;</p><p>Fauci said the goal should be to have a booster that induces a response against multiple potential variants.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna CEO says data for Omicron-specific shot likely available in March</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna CEO says data for Omicron-specific shot likely available in March\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-17 22:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/moderna-ceo-says-data-omicron-135958538.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Moderna Inc's vaccine candidate against the Omicron coronavirus variant will enter clinical development in the next few weeks and the company expects to be able to share data with regulators around ...</p>\n\n<a href=\"https://finance.yahoo.com/news/moderna-ceo-says-data-omicron-135958538.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4533":"AQR资本管理(全球第二大对冲基金)","BK4568":"美国抗疫概念","BNTX":"BioNTech SE","BK4532":"文艺复兴科技持仓","BK4551":"寇图资本持仓","BK4548":"巴美列捷福持仓","BK4535":"淡马锡持仓","MRNA":"Moderna, Inc.","BK4534":"瑞士信贷持仓","BK4139":"生物科技"},"source_url":"https://finance.yahoo.com/news/moderna-ceo-says-data-omicron-135958538.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2204577605","content_text":"Moderna Inc's vaccine candidate against the Omicron coronavirus variant will enter clinical development in the next few weeks and the company expects to be able to share data with regulators around March, CEO Stephane Bancel said on Monday.\"The vaccine is being finished ... it should be in the clinic in coming weeks. We are hoping in the March timeframe to be able to have data to share with regulators to figure out next steps,\" Bancel said at the World Economic Forum's virtual Davos Agenda conference.Moderna is also developing a single vaccine that combines a booster dose against COVID-19 with its experimental flu shot. ()Bancel said the best case scenario was the combined COVID/flu vaccine would be available by the fall of 2023, at least in some countries.\"Our goal is to be able to have a single annual booster so that we don't have compliance issues where people don't want to get two to three shots a winter.\"Many countries are already offering a third dose of a COVID-19 vaccine to their citizens, especially to older individuals and those who are immunocompromised, while Israel has started offering its citizens a fourth dose.Earlier in January, Moderna's CEO said people may need a fourth shot in the fall of 2022 as the efficacy of boosters against COVID-19 was likely to decline over the next few months.However, booster programs have met with skepticism from some disease experts over whether, and how widely, additional doses should become available, including the European Union's drug regulator, which has expressed doubts about the need for a fourth booster dose.Speaking at the same event, top U.S. infectious disease expert Anthony Fauci said there was no evidence that repeat booster doses would overwhelm the immune system.\"Giving boosters at different times, there is really no evidence that's going to hinder (immune response).\"Fauci said the goal should be to have a booster that induces a response against multiple potential variants.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9004065171,"gmtCreate":1642461175140,"gmtModify":1676533711657,"author":{"id":"3575234837042918","authorId":"3575234837042918","name":"Rbj","avatar":"https://static.tigerbbs.com/363acddaa9c1e92690a16e7dd67b6484","vip":1,"crmLevel":4,"crmLevelSwitch":0},"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9004065171","repostId":2204577605,"repostType":4,"repost":{"id":"2204577605","pubTimestamp":1642431461,"share":"https://www.laohu8.com/m/news/2204577605?lang=&edition=full","pubTime":"2022-01-17 22:57","market":"us","language":"en","title":"Moderna CEO says data for Omicron-specific shot likely available in March","url":"https://stock-news.laohu8.com/highlight/detail?id=2204577605","media":"Reuters","summary":"Moderna Inc's vaccine candidate against the Omicron coronavirus variant will enter clinical developm","content":"<html><head></head><body><p>Moderna Inc&#39;s vaccine candidate against the Omicron coronavirus variant will enter clinical development in the next few weeks and the company expects to be able to share data with regulators around March, CEO Stephane Bancel said on Monday.</p><p>&#34;The vaccine is being finished ... it should be in the clinic in coming weeks. We are hoping in the March timeframe to be able to have data to share with regulators to figure out next steps,&#34; Bancel said at the World Economic Forum&#39;s virtual Davos Agenda conference.</p><p>Moderna is also developing a single vaccine that combines a booster dose against COVID-19 with its experimental flu shot. ()</p><p>Bancel said the best case scenario was the combined COVID/flu vaccine would be available by the fall of 2023, at least in some countries.</p><p>&#34;Our goal is to be able to have a single annual booster so that we don&#39;t have compliance issues where people don&#39;t want to get two to three shots a winter.&#34;</p><p>Many countries are already offering a third dose of a COVID-19 vaccine to their citizens, especially to older individuals and those who are immunocompromised, while Israel has started offering its citizens a fourth dose.</p><p>Earlier in January, Moderna&#39;s CEO said people may need a fourth shot in the fall of 2022 as the efficacy of boosters against COVID-19 was likely to decline over the next few months.</p><p>However, booster programs have met with skepticism from some disease experts over whether, and how widely, additional doses should become available, including the European Union&#39;s drug regulator, which has expressed doubts about the need for a fourth booster dose.</p><p>Speaking at the same event, top U.S. infectious disease expert Anthony Fauci said there was no evidence that repeat booster doses would overwhelm the immune system.</p><p>&#34;Giving boosters at different times, there is really no evidence that&#39;s going to hinder (immune response).&#34;</p><p>Fauci said the goal should be to have a booster that induces a response against multiple potential variants.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna CEO says data for Omicron-specific shot likely available in March</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna CEO says data for Omicron-specific shot likely available in March\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-17 22:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/moderna-ceo-says-data-omicron-135958538.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Moderna Inc's vaccine candidate against the Omicron coronavirus variant will enter clinical development in the next few weeks and the company expects to be able to share data with regulators around ...</p>\n\n<a href=\"https://finance.yahoo.com/news/moderna-ceo-says-data-omicron-135958538.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4533":"AQR资本管理(全球第二大对冲基金)","BK4568":"美国抗疫概念","BNTX":"BioNTech SE","BK4532":"文艺复兴科技持仓","BK4551":"寇图资本持仓","BK4548":"巴美列捷福持仓","BK4535":"淡马锡持仓","MRNA":"Moderna, Inc.","BK4534":"瑞士信贷持仓","BK4139":"生物科技"},"source_url":"https://finance.yahoo.com/news/moderna-ceo-says-data-omicron-135958538.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2204577605","content_text":"Moderna Inc's vaccine candidate against the Omicron coronavirus variant will enter clinical development in the next few weeks and the company expects to be able to share data with regulators around March, CEO Stephane Bancel said on Monday.\"The vaccine is being finished ... it should be in the clinic in coming weeks. We are hoping in the March timeframe to be able to have data to share with regulators to figure out next steps,\" Bancel said at the World Economic Forum's virtual Davos Agenda conference.Moderna is also developing a single vaccine that combines a booster dose against COVID-19 with its experimental flu shot. ()Bancel said the best case scenario was the combined COVID/flu vaccine would be available by the fall of 2023, at least in some countries.\"Our goal is to be able to have a single annual booster so that we don't have compliance issues where people don't want to get two to three shots a winter.\"Many countries are already offering a third dose of a COVID-19 vaccine to their citizens, especially to older individuals and those who are immunocompromised, while Israel has started offering its citizens a fourth dose.Earlier in January, Moderna's CEO said people may need a fourth shot in the fall of 2022 as the efficacy of boosters against COVID-19 was likely to decline over the next few months.However, booster programs have met with skepticism from some disease experts over whether, and how widely, additional doses should become available, including the European Union's drug regulator, which has expressed doubts about the need for a fourth booster dose.Speaking at the same event, top U.S. infectious disease expert Anthony Fauci said there was no evidence that repeat booster doses would overwhelm the immune system.\"Giving boosters at different times, there is really no evidence that's going to hinder (immune response).\"Fauci said the goal should be to have a booster that induces a response against multiple potential variants.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9004062707,"gmtCreate":1642461110415,"gmtModify":1676533711626,"author":{"id":"3579412043719168","authorId":"3579412043719168","name":"jerwy","avatar":"https://static.tigerbbs.com/fdc16e3a47a2704d68f0ff55284feb48","vip":1,"hat":"https://static.tigerbbs.com/b0a2963eb37c60c5d6d4a8dbcd266952","crmLevel":3,"crmLevelSwitch":1},"htmlText":"wow&nbsp;","listText":"wow&nbsp;","text":"wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9004062707","repostId":2204577605,"repostType":4,"repost":{"id":"2204577605","pubTimestamp":1642431461,"share":"https://www.laohu8.com/m/news/2204577605?lang=&edition=full","pubTime":"2022-01-17 22:57","market":"us","language":"en","title":"Moderna CEO says data for Omicron-specific shot likely available in March","url":"https://stock-news.laohu8.com/highlight/detail?id=2204577605","media":"Reuters","summary":"Moderna Inc's vaccine candidate against the Omicron coronavirus variant will enter clinical developm","content":"<html><head></head><body><p>Moderna Inc&#39;s vaccine candidate against the Omicron coronavirus variant will enter clinical development in the next few weeks and the company expects to be able to share data with regulators around March, CEO Stephane Bancel said on Monday.</p><p>&#34;The vaccine is being finished ... it should be in the clinic in coming weeks. We are hoping in the March timeframe to be able to have data to share with regulators to figure out next steps,&#34; Bancel said at the World Economic Forum&#39;s virtual Davos Agenda conference.</p><p>Moderna is also developing a single vaccine that combines a booster dose against COVID-19 with its experimental flu shot. ()</p><p>Bancel said the best case scenario was the combined COVID/flu vaccine would be available by the fall of 2023, at least in some countries.</p><p>&#34;Our goal is to be able to have a single annual booster so that we don&#39;t have compliance issues where people don&#39;t want to get two to three shots a winter.&#34;</p><p>Many countries are already offering a third dose of a COVID-19 vaccine to their citizens, especially to older individuals and those who are immunocompromised, while Israel has started offering its citizens a fourth dose.</p><p>Earlier in January, Moderna&#39;s CEO said people may need a fourth shot in the fall of 2022 as the efficacy of boosters against COVID-19 was likely to decline over the next few months.</p><p>However, booster programs have met with skepticism from some disease experts over whether, and how widely, additional doses should become available, including the European Union&#39;s drug regulator, which has expressed doubts about the need for a fourth booster dose.</p><p>Speaking at the same event, top U.S. infectious disease expert Anthony Fauci said there was no evidence that repeat booster doses would overwhelm the immune system.</p><p>&#34;Giving boosters at different times, there is really no evidence that&#39;s going to hinder (immune response).&#34;</p><p>Fauci said the goal should be to have a booster that induces a response against multiple potential variants.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna CEO says data for Omicron-specific shot likely available in March</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna CEO says data for Omicron-specific shot likely available in March\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-17 22:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/moderna-ceo-says-data-omicron-135958538.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Moderna Inc's vaccine candidate against the Omicron coronavirus variant will enter clinical development in the next few weeks and the company expects to be able to share data with regulators around ...</p>\n\n<a href=\"https://finance.yahoo.com/news/moderna-ceo-says-data-omicron-135958538.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4533":"AQR资本管理(全球第二大对冲基金)","BK4568":"美国抗疫概念","BNTX":"BioNTech SE","BK4532":"文艺复兴科技持仓","BK4551":"寇图资本持仓","BK4548":"巴美列捷福持仓","BK4535":"淡马锡持仓","MRNA":"Moderna, Inc.","BK4534":"瑞士信贷持仓","BK4139":"生物科技"},"source_url":"https://finance.yahoo.com/news/moderna-ceo-says-data-omicron-135958538.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2204577605","content_text":"Moderna Inc's vaccine candidate against the Omicron coronavirus variant will enter clinical development in the next few weeks and the company expects to be able to share data with regulators around March, CEO Stephane Bancel said on Monday.\"The vaccine is being finished ... it should be in the clinic in coming weeks. We are hoping in the March timeframe to be able to have data to share with regulators to figure out next steps,\" Bancel said at the World Economic Forum's virtual Davos Agenda conference.Moderna is also developing a single vaccine that combines a booster dose against COVID-19 with its experimental flu shot. ()Bancel said the best case scenario was the combined COVID/flu vaccine would be available by the fall of 2023, at least in some countries.\"Our goal is to be able to have a single annual booster so that we don't have compliance issues where people don't want to get two to three shots a winter.\"Many countries are already offering a third dose of a COVID-19 vaccine to their citizens, especially to older individuals and those who are immunocompromised, while Israel has started offering its citizens a fourth dose.Earlier in January, Moderna's CEO said people may need a fourth shot in the fall of 2022 as the efficacy of boosters against COVID-19 was likely to decline over the next few months.However, booster programs have met with skepticism from some disease experts over whether, and how widely, additional doses should become available, including the European Union's drug regulator, which has expressed doubts about the need for a fourth booster dose.Speaking at the same event, top U.S. infectious disease expert Anthony Fauci said there was no evidence that repeat booster doses would overwhelm the immune system.\"Giving boosters at different times, there is really no evidence that's going to hinder (immune response).\"Fauci said the goal should be to have a booster that induces a response against multiple potential variants.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9004062557,"gmtCreate":1642461086832,"gmtModify":1676533711618,"author":{"id":"3582029110525423","authorId":"3582029110525423","name":"Whateverqw","avatar":"https://static.tigerbbs.com/7b82b69926257ee0d05417f42b935ac0","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Fast","listText":"Fast","text":"Fast","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9004062557","repostId":2204577605,"repostType":4,"repost":{"id":"2204577605","pubTimestamp":1642431461,"share":"https://www.laohu8.com/m/news/2204577605?lang=&edition=full","pubTime":"2022-01-17 22:57","market":"us","language":"en","title":"Moderna CEO says data for Omicron-specific shot likely available in March","url":"https://stock-news.laohu8.com/highlight/detail?id=2204577605","media":"Reuters","summary":"Moderna Inc's vaccine candidate against the Omicron coronavirus variant will enter clinical developm","content":"<html><head></head><body><p>Moderna Inc&#39;s vaccine candidate against the Omicron coronavirus variant will enter clinical development in the next few weeks and the company expects to be able to share data with regulators around March, CEO Stephane Bancel said on Monday.</p><p>&#34;The vaccine is being finished ... it should be in the clinic in coming weeks. We are hoping in the March timeframe to be able to have data to share with regulators to figure out next steps,&#34; Bancel said at the World Economic Forum&#39;s virtual Davos Agenda conference.</p><p>Moderna is also developing a single vaccine that combines a booster dose against COVID-19 with its experimental flu shot. ()</p><p>Bancel said the best case scenario was the combined COVID/flu vaccine would be available by the fall of 2023, at least in some countries.</p><p>&#34;Our goal is to be able to have a single annual booster so that we don&#39;t have compliance issues where people don&#39;t want to get two to three shots a winter.&#34;</p><p>Many countries are already offering a third dose of a COVID-19 vaccine to their citizens, especially to older individuals and those who are immunocompromised, while Israel has started offering its citizens a fourth dose.</p><p>Earlier in January, Moderna&#39;s CEO said people may need a fourth shot in the fall of 2022 as the efficacy of boosters against COVID-19 was likely to decline over the next few months.</p><p>However, booster programs have met with skepticism from some disease experts over whether, and how widely, additional doses should become available, including the European Union&#39;s drug regulator, which has expressed doubts about the need for a fourth booster dose.</p><p>Speaking at the same event, top U.S. infectious disease expert Anthony Fauci said there was no evidence that repeat booster doses would overwhelm the immune system.</p><p>&#34;Giving boosters at different times, there is really no evidence that&#39;s going to hinder (immune response).&#34;</p><p>Fauci said the goal should be to have a booster that induces a response against multiple potential variants.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna CEO says data for Omicron-specific shot likely available in March</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna CEO says data for Omicron-specific shot likely available in March\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-17 22:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/moderna-ceo-says-data-omicron-135958538.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Moderna Inc's vaccine candidate against the Omicron coronavirus variant will enter clinical development in the next few weeks and the company expects to be able to share data with regulators around ...</p>\n\n<a href=\"https://finance.yahoo.com/news/moderna-ceo-says-data-omicron-135958538.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4533":"AQR资本管理(全球第二大对冲基金)","BK4568":"美国抗疫概念","BNTX":"BioNTech SE","BK4532":"文艺复兴科技持仓","BK4551":"寇图资本持仓","BK4548":"巴美列捷福持仓","BK4535":"淡马锡持仓","MRNA":"Moderna, Inc.","BK4534":"瑞士信贷持仓","BK4139":"生物科技"},"source_url":"https://finance.yahoo.com/news/moderna-ceo-says-data-omicron-135958538.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2204577605","content_text":"Moderna Inc's vaccine candidate against the Omicron coronavirus variant will enter clinical development in the next few weeks and the company expects to be able to share data with regulators around March, CEO Stephane Bancel said on Monday.\"The vaccine is being finished ... it should be in the clinic in coming weeks. We are hoping in the March timeframe to be able to have data to share with regulators to figure out next steps,\" Bancel said at the World Economic Forum's virtual Davos Agenda conference.Moderna is also developing a single vaccine that combines a booster dose against COVID-19 with its experimental flu shot. ()Bancel said the best case scenario was the combined COVID/flu vaccine would be available by the fall of 2023, at least in some countries.\"Our goal is to be able to have a single annual booster so that we don't have compliance issues where people don't want to get two to three shots a winter.\"Many countries are already offering a third dose of a COVID-19 vaccine to their citizens, especially to older individuals and those who are immunocompromised, while Israel has started offering its citizens a fourth dose.Earlier in January, Moderna's CEO said people may need a fourth shot in the fall of 2022 as the efficacy of boosters against COVID-19 was likely to decline over the next few months.However, booster programs have met with skepticism from some disease experts over whether, and how widely, additional doses should become available, including the European Union's drug regulator, which has expressed doubts about the need for a fourth booster dose.Speaking at the same event, top U.S. infectious disease expert Anthony Fauci said there was no evidence that repeat booster doses would overwhelm the immune system.\"Giving boosters at different times, there is really no evidence that's going to hinder (immune response).\"Fauci said the goal should be to have a booster that induces a response against multiple potential variants.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9004062861,"gmtCreate":1642460953970,"gmtModify":1676533711625,"author":{"id":"3585255751373364","authorId":"3585255751373364","name":"MO75","avatar":"https://static.tigerbbs.com/d033068949889afd8c31c73da66c8e75","vip":1,"hat":"https://static.tigerbbs.com/b0a2963eb37c60c5d6d4a8dbcd266952","crmLevel":5,"crmLevelSwitch":0},"htmlText":"Siao. Like","listText":"Siao. Like","text":"Siao. Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9004062861","repostId":2204577605,"repostType":4,"repost":{"id":"2204577605","pubTimestamp":1642431461,"share":"https://www.laohu8.com/m/news/2204577605?lang=&edition=full","pubTime":"2022-01-17 22:57","market":"us","language":"en","title":"Moderna CEO says data for Omicron-specific shot likely available in March","url":"https://stock-news.laohu8.com/highlight/detail?id=2204577605","media":"Reuters","summary":"Moderna Inc's vaccine candidate against the Omicron coronavirus variant will enter clinical developm","content":"<html><head></head><body><p>Moderna Inc&#39;s vaccine candidate against the Omicron coronavirus variant will enter clinical development in the next few weeks and the company expects to be able to share data with regulators around March, CEO Stephane Bancel said on Monday.</p><p>&#34;The vaccine is being finished ... it should be in the clinic in coming weeks. We are hoping in the March timeframe to be able to have data to share with regulators to figure out next steps,&#34; Bancel said at the World Economic Forum&#39;s virtual Davos Agenda conference.</p><p>Moderna is also developing a single vaccine that combines a booster dose against COVID-19 with its experimental flu shot. ()</p><p>Bancel said the best case scenario was the combined COVID/flu vaccine would be available by the fall of 2023, at least in some countries.</p><p>&#34;Our goal is to be able to have a single annual booster so that we don&#39;t have compliance issues where people don&#39;t want to get two to three shots a winter.&#34;</p><p>Many countries are already offering a third dose of a COVID-19 vaccine to their citizens, especially to older individuals and those who are immunocompromised, while Israel has started offering its citizens a fourth dose.</p><p>Earlier in January, Moderna&#39;s CEO said people may need a fourth shot in the fall of 2022 as the efficacy of boosters against COVID-19 was likely to decline over the next few months.</p><p>However, booster programs have met with skepticism from some disease experts over whether, and how widely, additional doses should become available, including the European Union&#39;s drug regulator, which has expressed doubts about the need for a fourth booster dose.</p><p>Speaking at the same event, top U.S. infectious disease expert Anthony Fauci said there was no evidence that repeat booster doses would overwhelm the immune system.</p><p>&#34;Giving boosters at different times, there is really no evidence that&#39;s going to hinder (immune response).&#34;</p><p>Fauci said the goal should be to have a booster that induces a response against multiple potential variants.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna CEO says data for Omicron-specific shot likely available in March</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna CEO says data for Omicron-specific shot likely available in March\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-17 22:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/moderna-ceo-says-data-omicron-135958538.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Moderna Inc's vaccine candidate against the Omicron coronavirus variant will enter clinical development in the next few weeks and the company expects to be able to share data with regulators around ...</p>\n\n<a href=\"https://finance.yahoo.com/news/moderna-ceo-says-data-omicron-135958538.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4533":"AQR资本管理(全球第二大对冲基金)","BK4568":"美国抗疫概念","BNTX":"BioNTech SE","BK4532":"文艺复兴科技持仓","BK4551":"寇图资本持仓","BK4548":"巴美列捷福持仓","BK4535":"淡马锡持仓","MRNA":"Moderna, Inc.","BK4534":"瑞士信贷持仓","BK4139":"生物科技"},"source_url":"https://finance.yahoo.com/news/moderna-ceo-says-data-omicron-135958538.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2204577605","content_text":"Moderna Inc's vaccine candidate against the Omicron coronavirus variant will enter clinical development in the next few weeks and the company expects to be able to share data with regulators around March, CEO Stephane Bancel said on Monday.\"The vaccine is being finished ... it should be in the clinic in coming weeks. We are hoping in the March timeframe to be able to have data to share with regulators to figure out next steps,\" Bancel said at the World Economic Forum's virtual Davos Agenda conference.Moderna is also developing a single vaccine that combines a booster dose against COVID-19 with its experimental flu shot. ()Bancel said the best case scenario was the combined COVID/flu vaccine would be available by the fall of 2023, at least in some countries.\"Our goal is to be able to have a single annual booster so that we don't have compliance issues where people don't want to get two to three shots a winter.\"Many countries are already offering a third dose of a COVID-19 vaccine to their citizens, especially to older individuals and those who are immunocompromised, while Israel has started offering its citizens a fourth dose.Earlier in January, Moderna's CEO said people may need a fourth shot in the fall of 2022 as the efficacy of boosters against COVID-19 was likely to decline over the next few months.However, booster programs have met with skepticism from some disease experts over whether, and how widely, additional doses should become available, including the European Union's drug regulator, which has expressed doubts about the need for a fourth booster dose.Speaking at the same event, top U.S. infectious disease expert Anthony Fauci said there was no evidence that repeat booster doses would overwhelm the immune system.\"Giving boosters at different times, there is really no evidence that's going to hinder (immune response).\"Fauci said the goal should be to have a booster that induces a response against multiple potential variants.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":561,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}